**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 56804

**Manuscript Type:** REVIEW

**Role of novel biomarkers in kidney transplantation**

Swanson KJ *et al*. Biomarkers in kidney transplantation

Kurtis J Swanson, Fahad Aziz, Neetika Garg, Maha Mohamed, Didier Mandelbrot, Arjang Djamali, Sandesh Parajuli

**Kurtis J Swanson, Fahad Aziz, Neetika Garg, Maha Mohamed, Didier Mandelbrot, Sandesh Parajuli,** Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, United States

**Arjang Djamali,** Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, United States

**Author contributions:** Swanson K and Parajuli S had an original idea, designed the study, reviewed literature, prepared the manuscript; Aziz F, Garg N, Mohamed M, and Mandelbrot DA, and Djamali A edited the manuscript.

**Corresponding author: Sandesh Parajuli, MBBS, MD, Assistant Professor, Doctor,** Department of Medicine, University of Wisconsin School of Medicine and Public Health, 4175 UW Medical Foundation Centennial Building, 1685 Highland Avenue, Madison, WI 53705, United States. sparajuli@medicine.wisc.edu

**Received:** May 17, 2020

**Revised:** July 21, 2020

**Accepted:** August 25, 2020

**Published online:** September 18, 2020

**Abstract**

Clinical application of biomarkers is an integral component of transplant care. Clinicians and scientists alike are in search of betterbiomarkers than the current serologic (serum creatinine, donor-specific antibodies), urine-derived (urinalysis, urine protein), and histologic ones we now use. The science behind recent biomarker discovery spans across multiple molecular biologic disciplines, including transcriptomics, proteomics, and metabolomics. Innovative methodology and integration of basic and clinical approaches have allowed researchers to unearth molecular phenomena preceding clinical disease. Biomarkers can be classified in several ways. In this review, we have classified them *via* their origin and outcome: primarily immunologic, *i.e.*, representative of immune regulation and dysfunction and non-immunologic, pertaining to delayed graft function, cardiovascular events/mortality, infection, malignancy, post-transplant diabetes, graft, and patient survival. Novel biomarker uses to guide the diagnosis and management of transplant-related outcomes is a promising area of research. However, the use of biomarkers to predict outcomes after kidney transplantation is not well studied. In this review, we summarize the recent studies illustrating biomarker use and transplant outcomes.

**Key Words:** Biomarkers; Kidney Transplantation; Rejection; Infection; Mortality; Graft survival

**Citation:** Swanson KJ, Aziz F, Garg N, Mohamed M, Mandelbrot D, Djamali A, Parajuli S. Role of novel biomarkers in kidney transplantation. *World J Transplant* 2020; 10(9): 230-255

**URL:** https://www.wjgnet.com/2220-3230/full/v10/i9/230.htm

**DOI:** https://dx.doi.org/10.5500/wjt.v10.i9.230

**Core Tip:** Novel biomarkers are an emerging field within kidney transplantation, allowing innovative diagnostic and prognostic adjuncts to current standards of care. This review article aims to summarize the most recent literature describing novel biomarker use in kidney transplantation.

**INTRODUCTION**

Kidney transplantation is the optimal renal replacement therapy for patients with end-stage kidney disease (ESKD). Kidney transplant recipients (KTRs) experience survival benefits in all age groups, have improved health-related quality of life, and kidney transplantation is cost-effective compared to hemodialysis or peritoneal dialysis[1-3]. Surveillance of allograft dysfunction is integral to post-transplant management. Ideally, graft injury should be detected and treated before irreversible damage occurs. The gold standard for assessing kidney allografts has been histologic analysis *via* biopsy[4]. Allograft biopsies are imperfect, as they can miss early, reversible pathology. Also, they carry approximately a 1%-2% risk of significant complications[5].

Serial measures of glomerular filtration rate along with qualitative/quantitative measures of urine albumin have been the mainstay of allograft surveillance since they are non-invasive, readily available, and interpretable. Changes in these parameters, however, are often neither sensitive or specific, unpredictive of outcomes, and occur late in the disease[6]. This has led to the need for non-invasive predictive data to allow clinicians to more readily diagnose and manage allograft pathology: Novel biomarkers.

What is a biomarker? The National Institutes of Health Biomarker Definition Working Group provides the subsequent definition: A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic responses, or pharmacological responses to a therapeutic intervention[7]. Another definition per the World Health Organization is the following: Any substance, structure, or process that can be measured in the body or its products and influence or predict the incidence of outcome or disease[8].

In this review, our focus is to highlight biomarker use in the context of key kidney transplant outcomes. As such, we classified biomarkers based on immunological and non-immunological related outcomes. With immunological outcomes pertaining primarily to rejection and immune tolerance, this section offered an opportunity to stratify biomarkers further based on their relation to the immune system. The non-immunological section, which was highlighted by biomarkers related to tissue injury primarily, was categorized by meaningful outcomes to emphasize the predictive value of these biomarkers. In cases of the novel, unique pathways, further description is provided accordingly.

Over the past several years, the field of biomarker research has grown exponentially as scientists and physicians alike are searching for novel ways to non-invasively detect allograft perturbations early-to help guide management and prognosticate both allograft and patient outcomes. As seen in a commentary in 2018 regarding the most recent iteration of the Banff classification for rejection from 2017, language regarding “thoroughly validated gene transcripts/classifiers” as adjuncts to diagnose antibody-mediated rejection (ABMR) affirms the emergence of biomarkers as an additional tool to surveil and diagnose post-transplant pathology[9].

In this review, we aim to summarize the most current literature from the past 5 year (2015-present date) on novel biomarkers in kidney transplant recipients and their relevance to fundamental kidney transplant outcomes.

**NOVEL BIOMARKER CLASSIFICATION**

Novel biomarker use can be classified into 2 main categories: Immunologic and non-immunologic. Immunologic biomarkers are those characterizing immune dysfunction ranging from subclinical to overt rejection. Non-immunologic biomarkers are those that demonstrate adverse transplant outcomes whereby immune dysfunction is not the sole aberration at play, *e.g.*, delayed graft function, cardiovascular events, infection, malignancy. While an oversimplification, as innate and humoral immunity are rooted in most pathophysiologic responses, these categories provide a logical classification scheme for the myriad types of novel biomarkers.

***Immunological***

Surveillance and optimization of recipient immune status are vital to prolonged allograft and patient survival. While current practice offers means to risk-stratify patients for poor immunologic outcomes [human leukocyte antigen mismatch, sensitization, calculated panel reactive antibodies, pre-transplant donor-specific antibodies (DSA)], our current surveillance measures (creatinine, urine protein to creatinine ratio) fail to capture clinically unsuspected rejection, which occurs in 20%-25% of patients after kidney transplant [10]. In other words, early molecular level events occur below our current detection thresholds, leading to missed opportunities for intervention, prevention, and management of poor outcomes. Several recent studies offer promising findings to diagnose, treat, and prognosticate adverse immunologic outcomes.

**Chemokines:** Chemokines are signaling proteins capable of inducing movement of certain cell types to areas of interest. Chemokines arise early in the immune cascade of rejection and thus can act as biomarkers to non-invasively identify deleterious immune events. Both urine and plasma chemokines have been studied extensively to detect immunologic dysfunction.

In one study, Rabant *et al*[11] showed that urinary C-terminal amino acid sequence Cystine-X-Cystine (C-X-C) motif chemokines 9 and 10, interferon gamma (IFN-γ) dependent chemokines secreted by various leukocytes along with renal mesangial and tubular cells, correlated with tubulointerstitial and microvascular inflammation (t + i score; g + peritubular capillaritis score; all *P* < 0.001). The ratio of urinary C-X-C motif chemokine ligand ten (CXCL10) to urine creatinine diagnosed T cell-mediated rejection (TCMR) [area under the curve (AUC) = 0.80, 95% confidence interval (CI): 0.68-0.92; *P* < 0.001] and ABMR [AUC = 0.76 (95%CI: 0.69-0.82); *P* < 0.001]. Furthermore, CXCL10: Creatinine plus DSA improved diagnosis of ABMR [AUC= 0.83 (95%CI: 0.77-0.89); *P* < 0.001] and CXCL10: Creatinine ratio at the time of ABMR predicted risk of graft loss[11]. Similarly, Hricik *et al*[12] in their study from 2015 showed that positive urinary C-X-C motif chemokine ligand nine is predictive of acute rejection (AR) by a median of 15 d before clinical detection[12].

Urinary chemokines (C-X-C motif chemokine ligand nine specifically) were assessed for their predictive value of 5-year graft outcomes in a more recent study, but no clear association was observed[13].

Plasma-derived fractalkine, IFN-γ, and interferon gamma-induced protein ten were evaluated for prediction of AR in a recent study of 87 KTRs; the combined measure of fractalkine on day 0, interferon gamma-induced protein ten and IFN-γ on day 7 was predictive of AR in 1 mo (AUC= 0.866) with a sensitivity of 86.8% and a specificity of 89.8%[14]. In a recent study of 65 KTRs, interleukin (IL)-8 was found to predict rejection with higher levels at day 7, day 30 (*P* = 0.023, 0.038), and correlate with serum creatinine (Pearson *r* = 0.621, *P* = 0.001)[15].

Another promising biomarker is soluble cluster of differentiation thirty (CD30), a tumor necrosis factor glycoprotein derived from T cells that regulates the balance between T helper type 1 and T helper type 2 immune responses. Early post-transplant elevations within the first 2 wk in one study predicted AR (AUC= 0.775; *P* = 0.004) with the sensitivity of 88.8%, specificity of 46.3%[16]. These findings are summarized in Table 1.

In summary, chemokines have potential as novel biomarkers, particularly for predicting acute cellular and antibody-mediated rejection. Prediction of long term outcomes such as graft survival and patient survival, however, were limited. Chemokines may be a useful adjunct to predict early rejection events in kidney transplantation.

**Free micro ribonucleic acid:** Free micro ribonucleic acid (RNA) are small non-coding RNA segments integral to cellular function. While also present in homeostasis, in certain contexts, they signal perturbations at the molecular level, ergo are linked to disease. Free micro RNA have been studied extensively in renal pathology, both in native and transplanted kidneys. Given their regulatory roles and stability both *in vivo* and in vitro, they exude potential as robust biomarkers. Several recent studies demonstrate the role of free micro RNA as biomarkers[17].

In their 2016 study of 160 patients, Matz *et al*[17] showed that the expression levels of specific serum microRNAs miR-15B, miR-103A, and miR-106A discriminated patients with stable graft function significantly from patients with TCMR (*P* = 0.001996, 0.0054 and 0.0019 respectively) and from patients with urinary tract infection (*P* = 0.0001, < 0.0001 and = 0.0001)[17]. This group expounded on these findings with a later study, where they showed that miR-223-3p, miR-424-3p, and miR-145-5p distinguished TCMR and ABMR from stable graft function as well as identifying miR 145-5P as a distinct marker of interstitial fibrosis/tubular atrophy[18].

The utility of urine-derived free microRNA was demonstrated in a study of 80 KTRs from 2017 where urinary miR-155-5P predicted AR (AUC = 0.875; *P* = 0.046) with an 85% sensitivity and 86% specificity[19].

In a major study of 519 KTRs utilizing microRNA from allograft biopsies, Halloran *et al*[20] showed that use of a centralized microarray algorithm utilizing microRNA, the Molecular Microscope® Diagnostic System, can not only support histology (agreement between Molecular Microscope® Diagnostic System and histology 77% for TCMR, 77% ABMR, 76% no rejection with blinding to histology) but also is more consistent with clinical judgment (87%) than histology (80%) (*P* = 0.0042) in regards to select cases *n* = 451 biopsies)[20].

Ledeganck *et al*[21] provided the most comprehensive analysis of microRNAs in the context of kidney transplants in their recent review. They cited 11 studies whereby microRNA upregulation and downregulation were associated with TCMR, ABMR, and chronic ABMR. Across studies, consistently noted biomarkers include the following: miR-142, miR-155, miR-223 (upregulated) and miR-125, miR-30, miR-204 (downregulated)[21].

In their comprehensive review of novel biomarkers, Jamshaid *et al*[22] reported on a high grade study from 2015 by Lorenzen *et al*[23] examining long noncoding RNAs[22,23]. In their study of 93 KTRs (31 stable controls without rejection, 62 patients with AR, plus 10 samples from the rejection cohort after antirejection treatment), they found that RP11-354P17.15-001 (L328) was associated with acute TCMR (AUC = 0.76, *P* < 0.001; sensitivity 49%, specificity 95%). Moreover, L328 normalized after successful antirejection treatment. Interestingly, 51/62 patients presented with subclinical rejection, defined as no change in creatinine *i.e.* L328 was able to detect subclinical rejection[23]. A synopsis of these studies can be found in Table 2.

In summary, free microRNA appears to help discriminate rejection from non-rejection as well as subtypes of AR. Interestingly, these biomarkers were durable despite blinding to histology and consistent with clinical judgment as cited by Halloran *et al*[20] Free microRNA, particularly from allograft biopsy tissue, appears to enhance diagnosis of rejection and can supplement histology[20].

**Leukocyte subclasses:** The predominance and activity of different subclasses of leukocytes can indicate recipient immune status. Leukocyte populations thus can serve as biomarkers to detect and identify immune aberrancy preceding clinical disease.

One such population is donor-reactive memory B cells (mBCs). Donor-reactive memory B cells are a subset of the B cell pool with emerging data supportive of a robust response to alloantigen post-transplant[24]. In a 2018 study, mBCs were associated with rejection; in 85 KTRs who underwent for-cause biopsies, donor reactive mBCs were found in 100% patients with ABMR and *de novo* DSA. They were also present in 72%-80% of patients with chronic ABMR with and without DSA. In the 90 non-sensitized patients, mBC expansion occurred at a higher rate than de novo DSA and independently predicted ABMR [AUC= 0.917 (95%CI: 0.879-0.956); *P* < 0.001][25].

Donor-specific memory CD4 T cells have also been implicated in rejection. In their study from 2016, Gorbacheva *et al*[26] showed that in a murine model, mice sensitized with memory CD4 cells experienced an acute rise in serum creatinine > 1 mg/dL (1.7 ± 0.6 mg/dL by 6–8 d post-transplant) and developed allograft failure at 7 d. At the time of rejection, the recipient mice had high titers of DSA and increased frequencies of donor–reactive T cells producing IFN-γ compared with controls at matching time points[26].

Through the use of genomics in combination with histologic scoring, Yazdani *et al*[27] were able to derive specific immune cell types and demonstrate that the presence of natural killer (NK) cells are predictive of ABMR (AUC= 0.98, *P* < 0.001); ABMR *vs* TCMR (AUC= 0.91, *P* < 0.001) as well as ABMR histology. They found that 22/24 biopsies with microvascular inflammation (g + ptc) had elevated NK levels (AUC = 0.89, *P* < 0.0001). Moreover, activated NK cells had the best predictive capability of graft failure at 1-2 years compared to other leukocytes (AUC= 0.74). Notably, NK cell infiltration predicted graft failure independent of histologic diagnosis (*P* = 0.039)[27].

In their study from 2017, Cortes-Cerisuelo *et al*[28] found that in 23 KTRs receiving belatacept-based immunosuppression, patients with a higher frequency of cluster of differentiation twenty-eight and cluster of differentiation four T-cells experienced more rejection[28]. Though counterintuitive, the authors postulated that this was related to CD28+ cells exhibiting a pro-inflammatory phenotype relative to CD28-subset. With optimal cutoff determination, they were able to discriminate rejectors from non-rejectors with a sensitivity of 80% and specificity of 100%. Therefore, cluster of differentiation twenty-eight and cluster of differentiation four frequencies can act as a biomarker to determine optimal candidates for belatacept therapy. The studies mentioned above are summarized in Table 3.

In summary, leukocyte subclasses offer unique opportunities as biomarkers in that they (1) offer another vantage point into antigen-antibody dynamics that can occur independently of or preceding detectable donor-specific antibodies (2) highlight the role of less understood pathophysiologic mechanisms (NK cells) and their predictability of graft failure and (3) can potentially provide clinicians with an individualized recipient immune profile to guide management in terms of immunosuppression.

**Gene expression profiles:** Gene expression profiling (GEP) is an approach within the field of molecular biology whereby thousands of genes are analyzed simultaneously *via* messenger RNA to describe cellular function. Differential expression of genes, particularly those associated with immune cells and interleukins, are some of the earliest events leading to immune dysregulation and poor transplant outcomes. Consequently, these gene expression profiles can yield robust, viable biomarkers. Multiple encouraging profiles have been developed recently as cited below.

In their study of 307 KTRs from Clinical Trials in Organ Transplantation-8, Friedewald *et al*[10] created a rejection biomarker for subclinical acute rejection (sc-AR) based on GEP, which had the following characteristics: [sensitivity 64%, specificity 87%, positive predictive value (PPV) 61%, negative predictive value(NPV) 88%]. Moreover, their GEP biomarker was predictive of persistent subclinical AR[10].

A similar study examining the Genomics of Chronic Renal Allograft Rejection cohort led to the development of the Targeted Expression Assay, which allowed for the prediction of sc-AR at 3 mo in 113 KTRs (AUC= 0.830; NPV= 0.98, PPV = 0.79)[29].

A significant development in gene expression assays in kidney transplantation was the development of the Kidney Solid Organ Response Test. This is a 17 gene set created in 2014 that was found to detect AR accurately. Crespo *et al*[30] expanded on this work with the use of Kidney Solid Organ Response Test plus IFN-γ enzyme-linked immunosorbent spot assay in the Evaluation of Sub-Clinical Acute Rejection Prediction trial of 75 KTRs where they found that in combination, these assays synergistically can predict sc-AR, subclinical T cell-mediated rejection and subclinical antibody-mediated rejection (AUC> 0.85, *P* < 0.001)[30].

One of the most promising gene expression profiles is the TruGraf® Molecular diagnostic test, a non-invasive test to surveil patients with a stable renal function that is now reimbursed by Medicare. This test was first validated in 2014 whereby Kurian *et al*[31] showed that the TruGraf® GEP could distinguish patients with rejection from those with non-rejection dysfunction and excellent allograft function[31].

In 2019, First *et al*[32]expanded on these findings with TruGraf® in their study both retrospectively and prospectively. In their retrospective arm, they found that in the evaluation of 192 patients at 7 transplant centers, in 87.5% of the cases, investigators’ clinical decisions were influenced by TruGraf® test results. In the prospective arm of 45 patients at 5 centers, TruGraf® supported 87% of the clinical decisions with 93% of investigators stating they would use TruGraf® in subsequent patient care. In these studies, TruGraf® often led to the non-invasive diagnosis, affirming conservative approaches as well as obviating the need for biopsy[32].

Gene expression profiles can also be derived from urine, as demonstrated in a study from 2019, where a common rejection module of 11 genes was analyzed from 150 KTRs. Interestingly, an accurate prediction from 2 genes (Proteasome 20S Subunit Beta 9, CXCL10) was equivalent to the 11-gene model (sensitivity 93.6%, specificity 97.6%)[33]. Table 4 summarizes these studies.

In summary, gene expression profiles are promising biomarkers in surveilling immune status. As seen by their validation, reimbursement from the Centers for Medicare and Medicaid Services, and acceptance among investigators, gene expression profiles are helping to pave the way for broader use of biomarkers in kidney transplantation.

**Donor-derived cell-free deoxyribonucleic acid:** Allograft transplantation can be considered genome transplantation with grafts having a unique allogenomic signature. At baseline, cell-free deoxyribonucleic acid (DNA) is circulating at low levels. However, in the case of injury, including rejection, increased high levels of cell-free DNA are shed into the bloodstream and are thus measurable as a biomarker. Beck *et al*[34] described quantification and reference values for donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in their study from 2015[34]. Given this recent quantification, dd-cfDNA is a nascent area of research. Donor-derived cell-free DNA has been shown to predict the decline in estimated glomerular filtration rate (eGFR), de novo donor-specific antibody formation, and biopsy-proven rejection in multiple studies. Three recent studies highlight the utility of dd-dfDNA[35].

In their study of 189 KTRs, Oellerich *et al*[35] found that in patients with biopsy-proven rejection, median dd-cfDNA (cp/mL) was 3.3-fold and median dd-cfDNA (%) 2.0-fold higher than medians in stable patients without rejection. receiver operating characteristic analysis showed superior performance (*P* = 0.02), of measuring dd-cfDNA (cp/mL) (AUC= 0.83) compared to dd-cfDNA (%) (AUC= 0.73). Diagnostic odds ratios were 7.31 for dd-cfDNA (cp/mL), and 6.02 for dd-cfDNA (%) respectively. Remarkably, plasma creatinine showed a low correlation (Pearson *r* = 0.37) with dd-cfDNA (cp/mL)[35].

Stites *et al*[36] in examining 79 KTRs with TCMR 1A/borderline rejection found that forty-two patients had elevated dd-cfDNA compared to thirty-seven patients with low levels; elevated levels of dd-cfDNA predicted adverse clinical outcomes, including eGFR decline by 8.5% *vs* 0% in low dd-cfDNA patients (*P* = 0.004), de novo donor-specific antibody formation was seen in 40% (17/42) *vs* 2.7% (*P* < 0.0001), and future or persistent rejection occurred in 9 of 42 patients (21.4%) *vs* 0% (*P* = 0.003)[36].

One of the most important developments in dd-cfDNA technologies has been targeted next-generation sequencing techniques. These techniques allow for the quantification of dd-cfDNA without the need for the prior donor or recipient genotyping[37].

One of the more well-known assays, Allosure®, has been validated in several studies. Notably, Allosure® is commercially available and reimbursed by Medicare. In the study Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients study (ClinicalTrials.gov Identifier: NCT02424227) from 2017, it was shown to discriminate rejection from controls (AUC = 0.74, *P* < 0.0001; PPV= 61%, NPV= 84%); as well as ABMR from non-ABMR [AUC = 0.87 (95%CI: 0.75-0.97)][38]. Ongoing trials using Allosure® (clinical trials NCT04057742, NCT03326076) are being conducted at various transplant centers throughout the country.

In their comprehensive review on dd-cfDNA, Knight *et al*[39] cited 2 recent studies (Huang *et al*[40] and Whitlam *et al*[41]) of its application in the context of kidney transplantation[39-41]. In their study of 63 KTRs, Huang *et al*[40] found that dd-cfDNA discriminated patients with ABMR (median 1.35%; interquartile range (IQR): 1.10%-1.90%) compared to those with no rejection (median 0.38% (IQR: 0.26% to 1.10%); *P* < 0.001). dd-cfDNA did not distinguish TCMR from no rejection however. Whitlam *et al*[41] in their study of 61 KTRs, found that dd-cfDNA concentration and fraction were predictive of acute antibody-mediated rejection (aAMR) (AUC = 0.92, 0.85) and composite diagnosis of ABMR (AUC= 0.91, 0.89). Graft derived cell free DNA (gd-cfDNA) exhibited modest sensitivity (0.90; 0.85) and specificity (0.88, 0.79) for aAMR and ABMR[41]. These findings are summarized in Table 5.

Donor-derived cell-free DNA is a robust biomarker in predicting rejection outcomes. Moreover, there is evidence supporting its ability to predict longer-term outcomes. The use of dd-cfDNA as a supportive tool for diagnosis and management is already taking place with the implementation of Allosure® and other similar assays.

**Immune tolerance:** In addition to identifying immune dysfunction, biomarkers can reflect immune quiescence and tolerance in kidney transplant recipients. While this terminology is vague, Mathew *et al*[42] in their review, define immune tolerance nicely as “long-term allograft survival in the absence of immunosuppressive treatment and the presence of stable donor-specific immune responsiveness[42].” In one review, Chan-on *et al*[43] describe biomarker identification *via* differential expression from a tolerance group (stable graft function or healthy non-transplant volunteers) compared to a dysfunction group (acute or chronic rejection). They cite several potential biomarkers, including T cell, B cell, and macrophage populations, as well as genomic signatures from B and T cells along with microRNA[43]. In a recent review, Newell *et al*[44] describe that in 32 tolerant individuals, 31 genes (26 B cell-specific) distinguished tolerant from non-tolerant KTRs[44]. Two promising genes, cited in prior studies are B cell receptor genes immunoglobulin kappa variable 1D-13 and immunoglobulin kappa variable 4-1[44,45].

While less clear of an outcome than others described previously, immune tolerance is one of the primary aims after kidney transplantation. Having tools to validate and reassure clinicians beyond our current insensitive measures and/or detect early perturbations before overt disease manifests can improve patient care.

***Non-immunological***

The use of biomarkers to identify and predict transplant outcomes applies to non-immune related outcomes. In the following sections, various biomarkers will be discussed in the context of their non-immune outcomes.

**Graft quality:** Assessing allograft quality/viability is an essential step in kidney transplantation to appropriately allocate organs and predict future outcomes. With the incidence of ESKD increasing and improved transplant outcomes, the demand for donation continues to grow. Refined preservation techniques have helped to broaden the donor pool, giving way to viable donation with higher risk allografts. This in turn has narrowed the margin of error for prognosticating graft quality. In the past five years, biomarker discovery has emerged to help appraise potential allografts. Several robust studies are described below:

Parikh *et al*[46] described in their study of 671 KTRs that perfusate biomarkers of tissue injury were associated with 6-mo allograft function *via* eGFR: each doubling of perfusate neutrophil gelatinase-associated lipocalin (NGAL) and liver fatty acid-binding protein were independently associated with lower 6-mo eGFR (1.7 mL/min per 1.73 m2 ; 1.48 mL/min per 1.73 m2 respectively)[46].

Moser *et al*[47] in their study of 41 donor kidneys [16 Live donors, 16 donations after brain death (DBD); 9 donations after circulatory death (DCD)] undergoing machine cold perfusion, compared various tissue injury biomarkers. They found that tissue injury markers matrix metalloproteinase-2, lactate dehydrogenase, and NGAL were found in highest perfusate concentrations in DCD kidneys, followed by DBD and living donor allografts (all *P* < 0.0001)[47].

In their unique study comparing modified adenosine and lidocaine (AL) solution to the University of Wisconsin (UW) solution for organ preservation, Hamaoui *et al*[48] utilized perfusate lactate in addition to histology and perfusion dynamics to help compare viability. They found that in 10 DCD porcine kidneys perfused *via* hypothermic machine perfusion with modified AL solution had significantly lower perfusion lactate levels (3.1 mmol/L *vs* 4.1 mmol/L, *P* = 0.04) during reperfusion than those in UW solution. Of note, on histology, UW solution perfused kidneys had a greater degree of tubular dilatation than modified AL kidneys (*P* = 0.03). This demonstrates a potential application of perfusate lactate to detect ischemia-reperfusion injury[48].

A notable recent study is that of van Smaalen *et al*[49] from 2017. The investigators examined cytotoxic extracellular histones, which have been described as markers of cell injury (as seen in inflammation, thrombosis, sepsis namely) in 390 DCD kidney perfusates and sought to determine if their presence was associated with allograft viability. They found extracellular histone concentration was independently associated with 1-year graft failure [hazard ratio(HR)= 1.386 (95%CI: 1.037-1.853)]. Moreover, they observed that 1-year graft survival was improved for the low extracellular histone group (83% *vs* 71%, *P* = 0.008), which was maintained up to 5 years (76% *vs* 65%, *P* = 0.014)[49].

In their recent study from 2019, Weissenbacher *et al*[50] utilized perfusate allograft injury biomarkers NGAL and kidney injury molecule-1 (KIM-1) in addition to histology, urine output, sodium levels to help quantify allograft viability in the context of normothermic kidney perfusion with urine recirculation. While their study was limited in terms of size (11 allografts), lack of organ transplantation, and differing methods (urine recirculation *vs* not), the highest perfusate NGAL level was found in the lowest quality kidney (Kidney 4). In the perfused kidneys without urine recirculation, NGAL and KIM-1 decreased over time, but as the authors conclude, with such a small sample size, it is difficult to assign any predictive value based on this cohort[50].

In their review from 2020, De Beule *et al*[51] nicely summarize the current status of the allograft viability assessment. They illustrate potential roles for different biomarkers in different perfusion contexts *e.g.*, hypothermic, normothermic machine perfusion[51]. In the context of hypothermic machine perfusion, they, in conjunction with a recent meta-analysis performed by Guzzi *et al*[52] report that glutathione S-transferase and its isoforms alpha- and pi-, a family of detoxification enzymes associated with acute kidney injury and renal injury, have moderate predictive ability for delayed graft function (DGF)[52]. In terms of normothermic machine perfusion, few data exist. However, the authors describe potential roles for NGAL and endothelin-1 based on a trial of 56 discarded human kidneys after 1 h of normothermic machine perfusion. In this study, Hosgood *et al*[53] demonstrated that higher levels of urinary NGAL and endothelin-1 correlated with a higher *i.e.* worse *ex vivo* normothermic kidney perfusion score[53]. They also note that markers of acid-base homeostasis plus lactate and aspartate aminotransferase as demonstrated in the analysis of porcine perfusate after 8 h of normothermic machine perfusion correlated with posttransplant allograft function[54]. These studies are summarized in Table 6.

The aforementioned research demonstrates potential roles for biomarkers in adjunct with current scoring systems to help classify organs for appropriate allocation. While more research is needed, glutathione S-transferase as well as markers of tissue injury, namely NGAL, appear to show promise on this front.

**Delayed graft function:** Delayed graft function is a form of acute kidney injury defined by the need for renal replacement therapy in the first week after transplant. DGF is a significant transplant outcome as it is independently associated with AR and graft failure[55]. It is unknown, if biomarkers able to predict the incidence and duration of DGF early, could change management and improve outcomes.

Remarkably, biomarkers detectable within preservation solution during the peri-transplant period offer diagnostic/prognostic information regarding DGF. We will review several notable studies below:

Parikh *et al*[46] in their study cited previously also found that base NGAL concentration was significantly higher in allografts with DGF (*P* = 0.004). This was also observed in post values of IL-18 (*P* = 0.005), and base/post perfusate liver fatty acid-binding protein levels (*P* = 0.029, 0.006). After multivariate adjustment as well as delta concentration (post minus base) however, these biomarkers did not significantly correlate with DGF development[46]. Similarly, in another study, van den Akker *et al*[56] were able to demonstrate that NGAL at day one could predict DGF *vs* immediate graft function, and also NGAL level at day 1, 4 and 7 correlate with the duration of DGF[56].

Van Smaalen *et al*[49] in their study analyzing extracellular histone levels found that extracellular histone concentration was significantly higher in the DGF group (median 0.70 mg/mL (IQR: 0.43 to 0.98) compared to grafts that functioned immediately [median 0.42 mg/mL (IQR: 0.07 to 0.78); *P* < 0.001][49]. Curiously, there was no significant difference in extracellular histone concentration in grafts with primary non-function *vs* DGF (*P* = 0.437).

Van Balkom *et al*[57] showed that in 16 DCD kidneys in their discovery cohort, five perfusate proteins [leptin, granulocyte-macrophage colony-stimulating factor granulocyte-macrophage colony-stimulating factor (GM-CSF), periostin, plasminogen activator inhibitor-1 and osteopontin] out of 158 tested in addition to body mass index and dialysis duration predicted DGF. *Via* multivariate analysis, leptin and GM-CSF were found to be the most predictive. Subsequent validation with 40 kidneys found that leptin, GM-CSF + body mass index generated a highly predictive model of DGF [AUC= 0.89 (95%CI: 0.74-1.00)], which performed better than both kidney donor risk index and DGF risk calculator (AUC= 0.55, 0.59)[57].

In a recent study from 2019, Roest *et al*[58] found that in 8 allografts from both DCD and DBD donors, higher levels of perfusate microRNA mir-505-3p correlated with DGF (OR = 1.12, *P* = 0.028). This was confirmed in a validation cohort of 40 allografts, of which 20 developed DGF (*P* = 0.011). Interestingly, this predictive capability held true solely for DCD allografts (*P* = 0.009)[58].

In addition to perfusate markers, plasma and urine-derived biomarkers have been found to predict and prognosticate DGF. These biomarkers are associated with tissue injury. As described in several studies, both urine and plasma-derived NGAL were predictive of DGF development[59-63]. These were directly compared in the review by Li *et al*[64] In their review of 14 studies (8 evaluating urine NGAL, 6 evaluating plasma NGAL), the composite AUC for 24 h uNGAL was 0.91 (95%CI: 0.89-0.94) and the overall diagnostic OR for 24 h uNGAL was 24.17(95%CI: 9.94-58.75) with a sensitivity of 0.88 and a specificity of 0.81. The composite AUCfor 24 h blood neutrophil gelatinase-associated lipocalin was 0.95 (95%CI: 0.93-0.97) with an overall diagnostic OR for 24 h blood neutrophil gelatinase-associated lipocalin = 43.11 (95%CI: 16.43-113.12) with a sensitivity of 0.91 and a specificity of 0.86.

In another study, Bank *et al*[65], showed that urinary tissue inhibitor of metalloproteinases-2 decrease preceded resumption of allograft function and can predict DGF resolution[65].A unique study of DGF utilized microRNA and found that levels of homo sapiens-mature form of microRNA-217 (hsa-miR-217); hsa-miR-125b along with donor age and type of donation predicted DGF with a sensitivity of 61% and specificity of 91%[66]. The aforementioned comprehensive review from Ledeganck *et al*[21] cites 4 studies where biopsy samples of microRNA correlated with DGF. In these studies, the upregulation of miR-21-3P and miR-182-5p were measurable biomarkers[21]. Table 7 highlights these studies.

Biomarkers appear to be predictive of delayed graft function, as early as the peri-transplant period as demonstrated by perfusate markers. Urinary and plasma NGAL, among others, show promise and could augment care by changing management before the development of DGF as well as help prognosticate duration.

**Cardiovascular events/mortality:** Cardiovascular disease is the leading cause of death post-kidney transplantation[67]. Early detection and prediction of outcomes *via* novel biomarkers is a crucial area of research. Several recent studies have explored biomarker use concerning cardiovascular outcomes. Extensive biomarker research has been conducted using KTRs from the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) cohort[68-70].

Bansal *et al*[69] in 2016 examined 1027 KTRs from this cohort and found that each log increase in urine NGAL/creatinine independently associated with a 24% greater risk of cardiovascular events [adjusted hazard ratio(aHR) = 1.24 (95%CI: 1.06-1.45)], a 40% greater risk of graft failure [aHR = 1.40 (95%CI: 1.16-1.68)], and a 44% greater risk of death [aHR = 1.44 (95%CI: 1.26-1.65)]. Urine KIM-1/creatinine and IL-18/creatinine independently associated with a higher risk of death [aHR = 1.29 (95%CI: 1.03-1.61) and 1.25 (95%CI: 1.04-1.49 per log increase, respectively)][69].

In another study of 1184 KTRs, Park et al found that higher urine alpha 1 microglobulin (A1M) (HRper doubling of biomarker = 1.40 (95%CI: 1.21-1.62), monocyte chemoattractant protein-1 (MCP-1) [HR = 1.18 (95%CI: 1.03-1.36)], and procollagen type I intact N-terminal peptide [HR = 1.13 (95%CI: 1.03-1.23)] were associated with cardiovascular events, as well as death (HR per doubling A1M = 1.51 (95%CI: 1.32-1.72); HR per doubling MCP1 = 1.31 (95%CI: 1.13-1.51); *HR* per doubling procollagen type I intact N-terminal peptide = 1.11 (95%CI: 1.03-1.20)[70].

Interestingly, a study published in 2020 showed that soluble cardiac biomarker, a member of the IL-1 receptor family, which is predictive of cardiovascular mortality in patients with heart disease as well as those with chronic kidney disease, is associated with cardiovascular events [aHR = 1.31 (95%CI: 1.00-1.73); *P* = 0.054] and mortality [aHR = 1.61 (95%CI: 1.07-2.41); *P* = 0.022] in KTRs[71].

Another novel biomarker implicated in cardiovascular mortality is plasma malondialdehyde (MDA), as described in their study published in 2020. In this study, they showed that plasma MDA concentration was significantly associated with the risk for cardiovascular mortality after adjustment for potential confounders, including renal function, immunosuppressive therapy, smoking status, and blood pressure. This association was stronger in KTRs with decreased allograft function [eGFR ≤ 45 mL/min/1.73 m2; HR *=* 2.09 (95%CI: 1.45-3.00) per 1-standard deviation increment)][72]. The findings of these studies are summarized in Table 8.

In summary, multiple biomarkers show promise in predicting cardiovascular events and mortality. Analysis of the FAVORIT cohort and others with urinary biomarkers provides some of the most robust data in favor of biomarker use to supplement current standards of care. However, more unique biomarkers utilized in cardiovascular trials, namely cardiac biomarker, as well as other unique markers of inflammation, while needing more research, may also help to prognosticate cardiovascular outcomes.

**Infection:** Infections, both with common pathogens or opportunistic infections, are commonplace post-transplant due to induction and maintenance immunosuppression. Infection is a crucial outcome, as it is the second leading cause of death for KTRs[67]. Interestingly, novel biomarkers may help to stratify risk after transplant.

Plasma soluble cluster of differentiation 30 at baseline and at 1 mo were demonstrated in a study of 100 KTRs to predict bacterial infection [AUC = 0.633 (95%CI: 0.501-0.765); AUC = 0.846 (95%CI: 0.726-0.966)][73]. Similarly, Sadeghi *et al*[74] demonstrated that patients with post-transplant cytomegalovirus (CMV) were found to have higher levels of IL-23 (8.6 ± 4.4 *vs* 8.0 ± 17; *P* = 0.025) and IL-23/Cr ratios (*P* = 0.040) than patients without CMV disease after transplantation. Moreover, they showed that pre-transplant IL-23 > 7 pg/mL increases the risk for post-transplant CMV [relative risk = 4.50 (95%CI: 1.23 to 16.52); *P* = 0.023][74].

Genetic polymorphisms that modify recipient infection risk can be used as biomarkers. This was demonstrated in a study of 189 KTRs where a genetic polymorphism in the Nuclear Factor kappa-light-chain-enhancer of activated B cells-94ins/delATTG increased the risk of CMV infection; survival free from CMV infection was 54.7% for ins/ins group and 79.4% for deletion carriers one year after transplantation (*P*< 0.0001)[75]. Table 9 highlights the conclusions of these studies.

An important infection in KTRs is BK polyomavirus (BK). BK virus is a double-stranded DNA virus commonly observed in the general population as a commensal organism that can cause disease including ureteral stenosis, allograft nephropathy, and graft loss in kidney allograft recipients[76]. Several studies within the past 5 years have demonstrated the utility of novel biomarkers in identifying BK virus nephropathy (BKVN).

Kim *et al*[77] showed in their cross-sectional study from 385 KTRs that the presence of elevated BK urinary microRNAs bkv-miR-B1-5p and bkv-miR-B1-3p in KTRs with biopsy-proven BKVN were able to significantly distinguish them from recipients without the disease (AUC = 0.989, 0.985) [77]. While promising, the study was small with only 13 KTRs with BKVN.

Due to its ubiquity in the general population, the determination of the serostatus of the BK virus between donors and recipients is not standard. However, as shown by Abend *et al*[78] in their study of 116 deceased donor kidney transplant recipients, they found that donor BK virus antibody seropositivity correlated to post-transplant BK viremia (OR = 5.0 (95%CI: 1.9 to 12.7); *P* = 0.0001)[78]. The authors did not examine for BKVN however.

Serum and urine levels of CXCL10, have been demonstrated as a novel biomarkers in the context of rejection, as stated previously. In their recent study, Ho *et al*[79] demonstrated a further application for CXCL10 in terms of early BKVN. The authors observed elevated urine levels of CXCL10 in patients with subclinical BKVN. Elevated urinary CXCL10 occurred in the context of tubulointerstitial inflammation, peritubular capillaritis and BK viremia (all *P* < 0.05) They hypothesize that this could be due to either sampling error *vs* early disease preceding histologic phenomena whereby tubulointerstitial inflammation is only identifiable on a molecular level[79].

Upon its emergence in December 2019, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) coronavirus, also known as SARS-CoV-2 coronavirus (COVID19), has been one of the most impactful pandemics in recent history. Given the high virulence andhigh transmissibility of SARS-CoV-2 coronavirus, much research has gone into diagnosing and prognosticating coronavirus pneumonia. One such biomarker reported in both KTR and non-KTR literature is IL-6. Ahmadpoor *et al*[80] postulate key mechanisms for COVID 19 infection, noting that when an adaptive immune response is blunted, particularly in populations with low naïve T cells including KTRs, innate-immune mediated inflammation can persist and lead to cytokine storm and severe illness[80]. They refer to the study by Velazquez-Salinas *et al*[81] who described the role of IL-6 in animal and human viral infections (vesicular stomatitis virus, influenza pneumonia, hepatitis B, lymphocyte choriomeningitis virus namely), noting that IL-6 can lead to T-cell inhibition and mitigate cell-mediated antiviral responses potentiating this effect[81]. In light of this, IL-6 is being used as a biomarker and therapeutic target. In their case report describing a patient recovering from COVID19 pneumonia, Lauterio *et al*[82] illustrate the use of IL-6 as a biomarker and therapeutic target *via* the monoclonal antibody tocilizumab[82]. Currently, investigators in Italy are recruiting subjects in clinical trial NCT04317092, TOCIVID-19, examining the efficacy of tocilizumab therapy.

While a smaller area of study, biomarker use to predict infection is an emerging one, particularly in the context of newly surfacing disease *e.g.* COVID19. This could augment current biomarker research as learning about immune-related changes in the context of infection/infection risk will likely bolster our understanding of the immune system and have broad-ranging applications to immune responses after transplantation.

**Malignancy:** Malignancy is a common complication of kidney transplantation, likely related to the widespread immunologic changes related to induction/maintenance immunosuppression. The development of malignancy after transplant is a crucial outcome as it is the third leading cause of death for KTRs[67]. Biomarkers offer an opportunity for surveillance and prognostication before the development of the evident disease.

Hope *et al*[83] in their study of 82 KTRs (56 with known malignancy, 26 without) found that weak NK cell activity, derived from lactate dehydrogenase and interferon-gamma quantification using reactive T-cell enzyme-linked immunospot, was associated with metastatic cancer, cancer-related death, or septic death [HR *=* 2.1 (95%CI: 0.97 to 5.00)][83].

IL-27 was shown to discriminate patients with post-transplant neoplasia *vs* KTRs without cancer with a sensitivity of 81% specificity of 80% in a recent study[84].

In their study from 2019, Garnier *et al*[85] examined the pretransplant populations of cluster of differentiation forty five isoform with alternative mRNA splicing of exon (CD45RC) T cells in 89 KTRs. CD45RC expression dictates either a more regulatory (low expression) phenotype or pro-inflammatory (high expression) phenotype. Intriguingly, they found that differences in these populations predicted opposing outcomes: KTRs with a low CD4+CD45RC high population (< 51.9%) carried a 3.7 fold risk of cancer [HR= 3.71 (95%CI: 1.24 to 11.1); *P* = 0.019] *vs* the high CD4+CD45 high population having a 20-fold higher risk of rejection [HR = 21.7 (95%CI: 2.67 to 176.2); *P* = 0.0004][85]. The results of these studies are illustrated in Table 10.

While the literature on biomarker predicting malignancy after transplant is limited, these studies provide some interesting insights on immunoregulation and various adverse outcomes. While age-appropriate cancer screening, dermatology follow-up, and appropriate precautions are key tenets of post-transplant care, perhaps adjunctive testing conveying malignancy risk can reiterate their importance to clinicians and patients alike.

**Post-transplant diabetes:** Post-transplant diabetes mellitus (PTDM) is an adverse outcome after kidney transplantation, stemming from shared disease processes leading to ESKD along with diabetogenic conditions, including immunosuppression and inflammation. PTDM is an important outcome due to decreased allograft and patient survival[86]. Biomarkers have been studied to predict the development of this condition.

In one study, Heldal *et al*[87] studied 20 plasma biomarkers in 852 KTRs and found 6/20 significantly associated with the development of PTDM[87].

Similar to their prior work examining MDA in the context of cardiovascular outcomes, Yepes-Calderon *et al*[88] found that in Cox proportional-hazards regression analyses, MDA was inversely associated with PTDM, independent of immunosuppressive therapy, transplant-specific covariates, lifestyle, inflammation, and metabolism parameters [HR= 0.55 (95%CI: 0.36 to 0.83 per 1- standard deviation increase); *P* < 0.01][88]. The results of these studies are illustrated in Table 11.

Diabetes after transplant is a novel area of research in terms of predictive biomarkers. A need for more sensitive assays besides our current testing is needed to help change management and prevent/treat this disease. As demonstrated by the work from Yepes-Calderón *et al*[88], there is overlap with certain biomarkers and pathways in terms of cardiovascular health, diabetes, inflammation and thus more research in this realm will likely have larger implications in post-transplant disease processes.

**Graft survival**: With the goal of kidney transplant being to restore kidney function for a recipient’s lifespan, graft survival is critical. Unfortunately, transplantation, in most cases, is a form of renal replacement therapy, as allograft failure often precedes death. Novel biomarkers provide a non-invasive strategy to help prognosticate allograft survival.

Several recent studies on novel biomarker use address graft survival[16,63,68,69,89-91]. In their examination of the FAVORIT cohort, Ix *et al*[90] found that in 748 KTRs, urinary injury markers A1M and MCP-1 unadjusted [HRper doubling = 1.73 (95%CI: 1.43 to 2.08); HR per doubling = 1.60 (95%CI: 1.32 to 1.93)] and adjusted [aHR per doubling = 1.76 (95%CI: 1.27 to 2.44)]; aHR per doubling = 1.49 (95%CI: 1.17 to 1.89) were associated with allograft failure[90]. Similarly, Foster *et al*[68] found that in 508 KTRs from the FAVORIT cohort after multivariable adjustment, hazard ratios for eGFR measured by cystatin C and eGFR measured by beta-2-microglobulin < 30 *vs* 60+ were 9.49 (95CI: 4.28 to 21.00) and 15.53 (95%CI: 6.99 to 34.51; both *P* < 0.001) for kidney failure in stable kidney transplant recipients[68].

O’Connell *et al*[89] found that a 13-gene gene expression profile set predicted graft loss in their study of 204 KTRs at 2 (AUC = 0.842) and 3 years (AUC = 0.844), findings that were validated in 2 public data sets[89].

In their study published in 2018, Heylen *et al*[92] showed that ischemia during kidney transplantation leads to DNA hypermethylation, which is a long-lasting effect seen at 1-year post-transplantation and is associated with interstitial fibrosis (*P* < 0.001), vascular intima thickening (*P* = 0.003) and glomerulosclerosis (*P* < 0.001) on the 1-year protocol-specified biopsies[92].

A unique study from 2019 showed that in 133 KTRs, the higher absolute number of Treg cells 1 year after transplantation was significantly associated with improved 5-year survival (92.5% *vs* 81.4%, Log-rank *P* = 0.030). This finding was preserved after multivariate Cox regression analysis [hazard ratio for death-censored graft loss = 0.961 (95%CI: 0.924 to 0.998); *P* = 0.041], irrespective of 1-year proteinuria, and renal function[93].

**Patient survival:** In combination with graft survival, patient survival is one of (if not) the primary outcome(s) for kidney transplantation. Multiple studies specifically examined this in terms of cardiovascular mortality, as was mentioned previously[68-70].

One notable study utilizing 2 prospective biomarkers related to the lectin complement pathway, collectin liver-1 and collectin kidney-1 identified the following: high collectin liver-1 and collectin kidney-1 Levels at the time of transplantation were significantly associated with overall mortality in multivariate Cox analyses [HR = 1.50 (95%CI: 1.09-2.07); *P* = 0.013] and [HR= 1.43 (95%CI: 1.02-1.99); *P* = 0.038][91]. The cited studies on patient and graft survival are summarized in Table 12.

Graft and patient survival are the 2 major outcomes of interest after kidney transplantation. As previously stated, transplant across ranging allograft quality and donor/recipient characteristics is the optimal renal replacement strategy for survival. Even after the first year post-transplant, survival for KTRs is inferior to patients without ESKD. Narrowing this gap is a primary objective in transplantation. Perhaps with biomarker prediction/prognostication early (even as soon as hours after transplantation), more aggressive strategies can be undertaken to improve graft and patient survival. Moreover, they can complement current prognostication tools to help communicate impending poor outcomes with patients and prepare patients for next steps albeit graft failure and/or mortality.

**FUTURE POTENTIAL BIOMARKERS**

In our search, we queried a few particularly unique biomarkers/applications. In this section, we will briefly mention these findings.

In their proteomics study, Moser *et al*[47] described interesting findings in terms of alpha-one-antitrypsin levels across different deceased donor kidneys. They note that in a model of cardiac ischemia, alpha-one-antitrypsin was associated with anti-inflammatory and myocardium protection. As alpha-one antitrypsin is a clinically available therapeutic [AralastÒ (Baxter, United States), ZemeriaÒ (CSL Behring, United States), future studies of either animal models or human subjects could be conducted[47].

In their review, De Beule *et al*[51] postulated a potential biomarker role for flavin mononucleotide (FMN), a subunit of mitochondrial complex I. This molecule has been demonstrated in porcine kidney transplant models and human liver graft perfusion, as markers of mitochondrial, early allograft dysfunction and loss. This has not been studied in the context of human kidney transplantation[51].

DNA hypermethylation in the context of biomarker use in our search was a relatively unique approach, and showed promise, as mentioned earlier[92]. In a recently published review, Yang *et al*[94] combined multiple biomarker modalities, including urine chemokine CXCL10, clusterin, cell free deoxyribonucleic acid, methylated cell free deoxyribonucleic acid, urine protein, and urine creatinine into a comprehensive score, the Q score. In their evaluation of 601 KTRs, they were able to distinguish stable allograft function [median score = 13.1 (95%CI: 8.8-17.9] from AR [median score = 45.2 (95%CI: 40.8-57.9]; *P* < 0.00001). On aggregate, they found the Q score to be accurate [AUC = 9.99 (95%CI: 0.98-0.99); *P* < 0.00001] with a sensitivity of 95.2%, and specificity of 95.9[94]. De Vries *et al*[95] in their study evaluating the tryptophan/kynurenine pathway, one associated with a pro-inflammatory state, showed that in 561 KTRs, serum kynurenine and 3-hydroxykyurenine were independently associated with allograft failure [HR= 1.72 (95%CI: 1.23-2.41)][95].

Another unique study by Kostidis *et al*[96] from 2019 showed that urinary branched-chain amino acids over pyroglutamate and lactate over fumarate were predictive of prolonged delayed graft function (AUC = 0.85) [96].

B cell soluble factors have been implicated in autoimmune diseases such as systemic lupus erythematosus and exert the potential to be nascent biomarkers in the context of kidney transplantation. In their study published in 202, Irure-Ventura *et al*[97] showed that in 109 KTRs, pre-transplant B-cell activating factor (pg/mL) was significantly higher in patients with clinical ABMR during the first year (853.29 pg/mL (IQR: 765.37 to 1545.99 pg/mL) than kidney transplant without clinical rejection (594.60 pg/mL (IQR: 453.21-803.93 pg/mL) or controls (*P* = 0.003 and *P* < 0.001). This corresponded to an AUC = 0.784, with sensitivity 80%, and specificity of 73.3% for predicting ABMR within 12 mo of transplantation[97].

Novel biomarker use in kidney transplantation is a vibrant area of research with multiple pioneering approaches and strategies being undertaken to discern the complex pathophysiology after transplantation and improve patient care. As these studies demonstrate, there are myriad pathways and processes implicated in deleterious post-transplant outcomes. As we have described, several nascent biomarkers derived *via* multiple biomolceular disciplines confer similar predictive properties. As we gain understanding and familiarity with biomarkers, one can hope that scientists and clinicians alike will further incorporate biomarkers in a way analogous to the multi-domain testing inherent to clinical medicine. Perhaps this approach of combining biomarkers across various domains will work synergistically to advance the field of transplant medicine.

**CONCLUSION**

This article summarizes emerging research about novel biomarker use in kidney transplantation. Further innovation and integration of multiple disciplines/”omics” (transcriptomics, metabolomics, proteomics) will lead to advanced biomarker discovery and implementation, which in turn will augment our current standard of care to predict and enhance post-transplant outcomes.

**REFERENCES**

1 **Pesavento TE**. Kidney transplantation in the context of renal replacement therapy. *Clin J Am Soc Nephrol* 2009; **4**: 2035-2039 [PMID: 19850770 DOI: 10.2215/CJN.05500809]

2 **Fiebiger W**, Mitterbauer C, Oberbauer R. Health-related quality of life outcomes after kidney transplantation. *Health Qual Life Outcomes* 2004; **2**: 2 [PMID: 14713316 DOI: 10.1186/1477-7525-2-2]

3 **Parajuli S**, Clark DF, Djamali A. Is Kidney Transplantation a Better State of CKD? Impact on Diagnosis and Management. *Adv Chronic Kidney Dis* 2016; **23**: 287-294 [PMID: 27742382 DOI: 10.1053/j.ackd.2016.09.006]

4 **O'Callaghan JM**, Knight SR. Noninvasive biomarkers in monitoring kidney allograft health. *Curr Opin Organ Transplant* 2019; **24**: 411-415 [PMID: 31145158 DOI: 10.1097/MOT.0000000000000658]

5 **Redfield RR**, McCune KR, Rao A, Sadowski E, Hanson M, Kolterman AJ, Robbins J, Guite K, Mohamed M, Parajuli S, Mandelbrot DA, Astor BC, Djamali A. Nature, timing, and severity of complications from ultrasound-guided percutaneous renal transplant biopsy. *Transpl Int* 2016; **29**: 167-172 [PMID: 26284692 DOI: 10.1111/tri.12660]

6 **Bouamar R**, Shuker N, Hesselink DA, Weimar W, Ekberg H, Kaplan B, Bernasconi C, van Gelder T. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†). *Am J Transplant* 2013; **13**: 1253-1261 [PMID: 23480233 DOI: 10.1111/ajt.12191]

7 **Biomarkers Definitions Working Group**. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther* 2001; **69**: 89-95 [PMID: 11240971 DOI: 10.1067/mcp.2001.113989]

8 **Strimbu K**, Tavel JA. What are biomarkers? *Curr Opin HIV AIDS* 2010; **5**: 463-466 [PMID: 20978388 DOI: 10.1097/COH.0b013e32833ed177]

9 **Roufosse C**, Simmonds N, Clahsen-van Groningen M, Haas M, Henriksen KJ, Horsfield C, Loupy A, Mengel M, Perkowska-PtasiÅ„ska A, Rabant M, Racusen LC, Solez K, Becker JU. A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology. *Transplantation* 2018; **102**: 1795-1814 [PMID: 30028786 DOI: 10.1097/TP.0000000000002366]

10 **Friedewald JJ**, Kurian SM, Heilman RL, Whisenant TC, Poggio ED, Marsh C, Baliga P, Odim J, Brown MM, Ikle DN, Armstrong BD, Charette JI, Brietigam SS, Sustento-Reodica N, Zhao L, Kandpal M, Salomon DR, Abecassis MM; Clinical Trials in Organ Transplantation 08 (CTOT-08). Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant. *Am J Transplant* 2019; **19**: 98-109 [PMID: 29985559 DOI: 10.1111/ajt.15011]

11 **Rabant M**, Amrouche L, Lebreton X, Aulagnon F, Benon A, Sauvaget V, Bonifay R, Morin L, Scemla A, Delville M, Martinez F, Timsit MO, Duong Van Huyen JP, Legendre C, Terzi F, Anglicheau D. Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection. *J Am Soc Nephrol* 2015; **26**: 2840-2851 [PMID: 25948873 DOI: 10.1681/ASN.2014080797]

12 **Hricik DE**, Formica RN, Nickerson P, Rush D, Fairchild RL, Poggio ED, Gibson IW, Wiebe C, Tinckam K, Bunnapradist S, Samaniego-Picota M, Brennan DC, Schröppel B, Gaber O, Armstrong B, Ikle D, Diop H, Bridges ND, Heeger PS; Clinical Trials in Organ Transplantation-09 Consortium. Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. *J Am Soc Nephrol* 2015; **26**: 3114-3122 [PMID: 25925687 DOI: 10.1681/ASN.2014121234]

13 **Faddoul G**, Nadkarni GN, Bridges ND, Goebel J, Hricik DE, Formica R, Menon MC, Morrison Y, Murphy B, Newell K, Nickerson P, Poggio ED, Rush D, Heeger PS; CTOT-17 consortium. Analysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes: Results From Clinical Trials in Organ Transplantation-17. *Transplantation* 2018; **102**: 673-680 [PMID: 29189482 DOI: 10.1097/TP.0000000000002026]

14 **Xu CX**, Shi BY, Jin ZK, Hao JJ, Duan WL, Han F, Zhao YL, Ding CG, Xue WJ, Ding XM, Zheng J, Tian PX. Multiple-biomarkers provide powerful prediction of early acute renal allograft rejection by combination of serum fractalkine, IFN-γ and IP-10. *Transpl Immunol* 2018; **50**: 68-74 [PMID: 30081186 DOI: 10.1016/j.trim.2018.08.003]

15 **Tefik T**, Ciftci HÅž, Karadeniz MS, Yazici H, Oktar T, Kocak T, Ziylan O, Turkmen A, OÄŸuz FS, Nane I. Predictive Value of Interleukin 2 and Interleukin 8 on Early Rejection in Living Related Kidney Transplant Recipients. *Transplant Proc* 2019; **51**: 1078-1081 [PMID: 31101174 DOI: 10.1016/j.transproceed.2019.02.015]

16 **de Holanda MI**, Matuck T, de Carvalho DDBM, Domingues EMFL, Curvo R, Glasberg DS, Santos AMG, Borela ÁM, Pôrto LC. Soluble CD30, Acute Rejection, and Graft Survival: Pre- and 6-Month Post-Transplant Determinations-When Is the Best Time to Measure? *Transplant Proc* 2018; **50**: 728-736 [PMID: 29661425 DOI: 10.1016/j.transproceed.2018.02.025]

17 **Matz M**, Lorkowski C, Fabritius K, Durek P, Wu K, Rudolph B, Neumayer HH, Mashreghi MF, Budde K. Free microRNA levels in plasma distinguish T-cell mediated rejection from stable graft function after kidney transplantation. *Transpl Immunol* 2016; **39**: 52-59 [PMID: 27663089 DOI: 10.1016/j.trim.2016.09.001]

18 **Matz M**, Heinrich F, Lorkowski C, Wu K, Klotsche J, Zhang Q, Lachmann N, Durek P, Budde K, Mashreghi MF. MicroRNA regulation in blood cells of renal transplanted patients with interstitial fibrosis/tubular atrophy and antibody-mediated rejection. *PLoS One* 2018; **13**: e0201925 [PMID: 30102719 DOI: 10.1371/journal.pone.0201925]

19 **Millán O**, Budde K, Sommerer C, Aliart I, Rissling O, Bardaji B, Matz M, Zeier M, Silva I, Guirado L, Brunet M. Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. *Br J Clin Pharmacol* 2017; **83**: 2636-2650 [PMID: 28880456 DOI: 10.1111/bcp.13399]

20 **Halloran PF**, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D, Bromberg J, Einecke G, Eskandary F, Gosset C, Duong Van Huyen JP, Gupta G, Lefaucheur C, Malone A, Mannon RB, Seron D, Sellares J, Weir M, Loupy A. Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study. *Am J Transplant* 2017; **17**: 2851-2862 [PMID: 28449409 DOI: 10.1111/ajt.14329]

21 **Ledeganck KJ**, Gielis EM, Abramowicz D, Stenvinkel P, Shiels PG, Van Craenenbroeck AH. MicroRNAs in AKI and Kidney Transplantation. *Clin J Am Soc Nephrol* 2019; **14**: 454-468 [PMID: 30602462 DOI: 10.2215/CJN.08020718]

22 **Jamshaid F**, Froghi S, Di Cocco P, Dor FJ. Novel non-invasive biomarkers diagnostic of acute rejection in renal transplant recipients: A systematic review. *Int J Clin Pract* 2018; : e13220 [PMID: 30011113 DOI: 10.1111/ijcp.13220]

23 **Lorenzen JM**, Schauerte C, Kölling M, Hübner A, Knapp M, Haller H, Thum T. Long Noncoding RNAs in Urine Are Detectable and May Enable Early Detection of Acute T Cell-Mediated Rejection of Renal Allografts. *Clin Chem* 2015; **61**: 1505-1514 [PMID: 26506996 DOI: 10.1373/clinchem.2015.243600]

24 **Lúcia M**, Luque S, Crespo E, Melilli E, Cruzado JM, Martorell J, Jarque M, Gil-Vernet S, Manonelles A, Grinyó JM, Bestard O. Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation. *Kidney Int* 2015; **88**: 874-887 [PMID: 26176829 DOI: 10.1038/ki.2015.205]

25 **Luque S**, Lúcia M, Melilli E, Lefaucheur C, Crespo M, Loupy A, Bernal-Casas D, Gomà M, Jarque M, Crespo E, Montero N, Manonelles A, Cruzado JM, Gil-Vernet S, Grinyó JM, Bestard O. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation. *Am J Transplant* 2019; **19**: 368-380 [PMID: 30085394 DOI: 10.1111/ajt.15055]

26 **Gorbacheva V**, Fan R, Fairchild RL, Baldwin WM 3rd, Valujskikh A. Memory CD4 T Cells Induce Antibody-Mediated Rejection of Renal Allografts. *J Am Soc Nephrol* 2016; **27**: 3299-3307 [PMID: 27020853 DOI: 10.1681/ASN.2015080848]

27 **Yazdani S**, Callemeyn J, Gazut S, Lerut E, de Loor H, Wevers M, Heylen L, Saison C, Koenig A, Thaunat O, Thorrez L, Kuypers D, Sprangers B, Noël LH, Van Lommel L, Schuit F, Essig M, Gwinner W, Anglicheau D, Marquet P, Naesens M. Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation. *Kidney Int* 2019; **95**: 188-198 [PMID: 30396694 DOI: 10.1016/j.kint.2018.08.027]

28 **Cortes-Cerisuelo M**, Laurie SJ, Mathews DV, Winterberg PD, Larsen CP, Adams AB, Ford ML. Increased Pretransplant Frequency of CD28+ CD4+ TEM Predicts Belatacept-Resistant Rejection in Human Renal Transplant Recipients. *Am J Transplant* 2017; **17**: 2350-2362 [PMID: 28502091 DOI: 10.1111/ajt.14350]

29 **Zhang W**, Yi Z, Keung KL, Shang H, Wei C, Cravedi P, Sun Z, Xi C, Woytovich C, Farouk S, Huang W, Banu K, Gallon L, Magee CN, Najafian N, Samaniego M, Djamali A, Alexander SI, Rosales IA, Smith RN, Xiang J, Lerut E, Kuypers D, Naesens M, O'Connell PJ, Colvin R, Menon MC, Murphy B. A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. *J Am Soc Nephrol* 2019; **30**: 1481-1494 [PMID: 31278196 DOI: 10.1681/ASN.2018111098]

30 **Crespo E**, Roedder S, Sigdel T, Hsieh SC, Luque S, Cruzado JM, Tran TQ, Grinyó JM, Sarwal MM, Bestard O. Molecular and Functional Noninvasive Immune Monitoring in the ESCAPE Study for Prediction of Subclinical Renal Allograft Rejection. *Transplantation* 2017; **101**: 1400-1409 [PMID: 27362314 DOI: 10.1097/TP.0000000000001287]

31 **Kurian SM**, Williams AN, Gelbart T, Campbell D, Mondala TS, Head SR, Horvath S, Gaber L, Thompson R, Whisenant T, Lin W, Langfelder P, Robison EH, Schaffer RL, Fisher JS, Friedewald J, Flechner SM, Chan LK, Wiseman AC, Shidban H, Mendez R, Heilman R, Abecassis MM, Marsh CL, Salomon DR. Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling. *Am J Transplant* 2014; **14**: 1164-1172 [PMID: 24725967 DOI: 10.1111/ajt.12671]

32 **First MR**, Peddi VR, Mannon R, Knight R, Marsh CL, Kurian SM, Rice JC, Maluf D, Mandelbrot D, Patel A, David J, Schieve C, Lee D, Lewis P, Friedewald JJ, Abecassis MM, Rose S. Investigator Assessment of the Utility of the TruGraf Molecular Diagnostic Test in Clinical Practice. *Transplant Proc* 2019; **51**: 729-733 [PMID: 30979457 DOI: 10.1016/j.transproceed.2018.10.024]

33 **Sigdel TK**, Yang JYC, Bestard O, Schroeder A, Hsieh SC, Liberto JM, Damm I, Geraedts ACM, Sarwal MM. A urinary Common Rejection Module (uCRM) score for non-invasive kidney transplant monitoring. *PLoS One* 2019; **14**: e0220052 [PMID: 31365568 DOI: 10.1371/journal.pone.0220052]

34 **Beck J**, Oellerich M, Schulz U, Schauerte V, Reinhard L, Fuchs U, Knabbe C, Zittermann A, Olbricht C, Gummert JF, Shipkova M, Birschmann I, Wieland E, Schütz E. Donor-Derived Cell-Free DNA Is a Novel Universal Biomarker for Allograft Rejection in Solid Organ Transplantation. *Transplant Proc* 2015; **47**: 2400-2403 [PMID: 26518940 DOI: 10.1016/j.transproceed.2015.08.035]

35 **Oellerich M**, Shipkova M, Asendorf T, Walson PD, Schauerte V, Mettenmeyer N, Kabakchiev M, Hasche G, Gröne HJ, Friede T, Wieland E, Schwenger V, Schütz E, Beck J. Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. *Am J Transplant* 2019; **19**: 3087-3099 [PMID: 31062511 DOI: 10.1111/ajt.15416]

36 **Stites E**, Kumar D, Olaitan O, John Swanson S, Leca N, Weir M, Bromberg J, Melancon J, Agha I, Fattah H, Alhamad T, Qazi Y, Wiseman A, Gupta G. High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury. *Am J Transplant* 2020; : [PMID: 32056331 DOI: 10.1111/ajt.15822]

37 **Dengu F**. Next-generation sequencing methods to detect donor-derived cell-free DNA after transplantation. *Transplant Rev (Orlando)* 2020; **34**: 100542 [PMID: 32265093 DOI: 10.1016/j.trre.2020.100542]

38 **Bloom RD**, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, Matas AJ, Mehta S, Mannon RB, Sharfuddin A, Fischbach B, Narayanan M, Jordan SC, Cohen D, Weir MR, Hiller D, Prasad P, Woodward RN, Grskovic M, Sninsky JJ, Yee JP, Brennan DC; Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators. Cell-Free DNA and Active Rejection in Kidney Allografts. *J Am Soc Nephrol* 2017; **28**: 2221-2232 [PMID: 28280140 DOI: 10.1681/ASN.2016091034]

39 **Knight SR**, Thorne A, Lo Faro ML. Donor-specific Cell-free DNA as a Biomarker in Solid Organ Transplantation. A Systematic Review. *Transplantation* 2019; **103**: 273-283 [PMID: 30308576 DOI: 10.1097/TP.0000000000002482]

40 **Huang E**, Sethi S, Peng A, Najjar R, Mirocha J, Haas M, Vo A, Jordan SC. Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients. *Am J Transplant* 2019; **19**: 1663-1670 [PMID: 30725531 DOI: 10.1111/ajt.15289]

41 **Whitlam JB**, Ling L, Skene A, Kanellis J, Ierino FL, Slater HR, Bruno DL, Power DA. Diagnostic application of kidney allograft-derived absolute cell-free DNA levels during transplant dysfunction. *Am J Transplant* 2019; **19**: 1037-1049 [PMID: 30312536 DOI: 10.1111/ajt.15142]

42 **Mathew JM**, Ansari MJ, Gallon L, Leventhal JR. Cellular and functional biomarkers of clinical transplant tolerance. *Hum Immunol* 2018; **79**: 322-333 [PMID: 29374560 DOI: 10.1016/j.humimm.2018.01.009]

43 **Chan-On C**, Liberto JM, Sarwal MM. Mechanisms and biomarkers of immune quiescence in kidney transplantation. *Hum Immunol* 2018; **79**: 356-361 [PMID: 29408630 DOI: 10.1016/j.humimm.2018.01.016]

44 **Newell KA**, Adams AB, Turka LA. Biomarkers of operational tolerance following kidney transplantation - The immune tolerance network studies of spontaneously tolerant kidney transplant recipients. *Hum Immunol* 2018; **79**: 380-387 [PMID: 29448053 DOI: 10.1016/j.humimm.2018.02.007]

45 **Asare A**, Kanaparthi S, Lim N, Phippard D, Vincenti F, Friedewald J, Pavlakis M, Poggio E, Heeger P, Mannon R, Burrell BE, Morrison Y, Bridges N, Sanz I, Chandraker A, Newell KA, Turka LA. B Cell Receptor Genes Associated With Tolerance Identify a Cohort of Immunosuppressed Patients With Improved Renal Allograft Graft Function. *Am J Transplant* 2017; **17**: 2627-2639 [PMID: 28371372 DOI: 10.1111/ajt.14283]

46 **Parikh CR**, Hall IE, Bhangoo RS, Ficek J, Abt PL, Thiessen-Philbrook H, Lin H, Bimali M, Murray PT, Rao V, Schröppel B, Doshi MD, Weng FL, Reese PP. Associations of Perfusate Biomarkers and Pump Parameters With Delayed Graft Function and Deceased Donor Kidney Allograft Function. *Am J Transplant* 2016; **16**: 1526-1539 [PMID: 26695524 DOI: 10.1111/ajt.13655]

47 **Moser MAJ**, Sawicka K, Arcand S, O'Brien P, Luke P, Beck G, Sawicka J, Cohen A, Sawicki G. Proteomic Analysis of Perfusate from Machine Cold Perfusion of Transplant Kidneys: Insights Into Protection from Injury. *Ann Transplant* 2017; **22**: 730-739 [PMID: 29217818 DOI: 10.12659/aot.905347]

48 **Hamaoui K**, Aftab A, Gowers S, Boutelle M, Cook T, Rudd D, Dobson GP, Papalois V. An ex vivo comparison of adenosine and lidocaine solution and University of Wisconsin solution for hypothermic machine perfusion of porcine kidneys: potential for development. *J Surg Res* 2017; **208**: 219-229 [PMID: 27993213 DOI: 10.1016/j.jss.2016.08.068]

49 **van Smaalen TC**, Beurskens DM, Hoogland ER, Winkens B, Christiaans MH, Reutelingsperger CP, van Heurn LW, Nicolaes GA. Presence of Cytotoxic Extracellular Histones in Machine Perfusate of Donation After Circulatory Death Kidneys. *Transplantation* 2017; **101**: e93-e101 [PMID: 27906828 DOI: 10.1097/TP.0000000000001590]

50 **Weissenbacher A**, Lo Faro L, Boubriak O, Soares MF, Roberts IS, Hunter JP, Voyce D, Mikov N, Cook A, Ploeg RJ, Coussios CC, Friend PJ. Twenty-four-hour normothermic perfusion of discarded human kidneys with urine recirculation. *Am J Transplant* 2019; **19**: 178-192 [PMID: 29758129 DOI: 10.1111/ajt.14932]

51 **De Beule J**, Jochmans I. Kidney Perfusion as an Organ Quality Assessment Tool-Are We Counting Our Chickens Before They Have Hatched? *J Clin Med* 2020; **9**: 879 [PMID: 32210197 DOI: 10.3390/jcm9030879]

52 **Guzzi F**, Knight SR, Ploeg RJ, Hunter JP. A systematic review to identify whether perfusate biomarkers produced during hypothermic machine perfusion can predict graft outcomes in kidney transplantation. *Transpl Int* 2020; **33**: 590-602 [PMID: 32031281 DOI: 10.1111/tri.13593]

53 **Hosgood SA**, Nicholson ML. An Assessment of Urinary Biomarkers in a Series of Declined Human Kidneys Measured During Ex Vivo Normothermic Kidney Perfusion. *Transplantation* 2017; **101**: 2120-2125 [PMID: 27681269 DOI: 10.1097/TP.0000000000001504]

54 **Kaths JM**, Hamar M, Echeverri J, Linares I, Urbanellis P, Cen JY, Ganesh S, Dingwell LS, Yip P, John R, Bagli D, Mucsi I, Ghanekar A, Grant D, Robinson LA, Selzner M. Normothermic *ex vivo* kidney perfusion for graft quality assessment prior to transplantation. *Am J Transplant* 2018; **18**: 580-589 [PMID: 28889600 DOI: 10.1111/ajt.14491]

55 **Yarlagadda SG**, Coca SG, Formica RN Jr, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. *Nephrol Dial Transplant* 2009; **24**: 1039-1047 [PMID: 19103734 DOI: 10.1093/ndt/gfn667]

56 **van den Akker EK**, Hesselink DA, Manintveld OC, IJzermans JN, de Bruijn RW, Dor FJ. Neutrophil Gelatinase-Associated Lipocalin, but Not Kidney Injury Marker 1, Correlates with Duration of Delayed Graft Function. *Eur Surg Res* 2015; **55**: 319-327 [PMID: 26451602 DOI: 10.1159/000440718]

57 **van Balkom BWM**, Gremmels H, Ooms LSS, Toorop RJ, Dor FJMF, de Jong OG, Michielsen LA, de Borst GJ, de Jager W, Abrahams AC, van Zuilen AD, Verhaar MC. Proteins in Preservation Fluid as Predictors of Delayed Graft Function in Kidneys from Donors after Circulatory Death. *Clin J Am Soc Nephrol* 2017; **12**: 817-824 [PMID: 28476951 DOI: 10.2215/CJN.10701016]

58 **Roest HP**, Ooms LSS, Gillis AJM, IJzermans JNM, Looijenga LHJ, Dorssers LCJ, Dor FJMF, van der Laan LJW. Cell-free MicroRNA miR-505-3p in Graft Preservation Fluid Is an Independent Predictor of Delayed Graft Function After Kidney Transplantation. *Transplantation* 2019; **103**: 329-335 [PMID: 30444806 DOI: 10.1097/TP.0000000000002527]

59 **Truche AS**, Trocme C, Vergnaud S, Janbon B, Giovannini D, Malvezzi P, Moreau-Gaudry X, Rostaing L, Tetaz R. Early Prediction of Graft Outcomes After Kidney Transplantation From Donors After Circulatory Death: Biomarkers and Transplantation Characteristics. *Transplant Proc* 2019; **51**: 3234-3243 [PMID: 31732205 DOI: 10.1016/j.transproceed.2019.09.009]

60 **Pianta TJ**, Peake PW, Pickering JW, Kelleher M, Buckley NA, Endre ZH. Clusterin in kidney transplantation: novel biomarkers *vs* serum creatinine for early prediction of delayed graft function. *Transplantation* 2015; **99**: 171-179 [PMID: 25083615 DOI: 10.1097/TP.0000000000000256]

61 **Reese PP**, Hall IE, Weng FL, Schröppel B, Doshi MD, Hasz RD, Thiessen-Philbrook H, Ficek J, Rao V, Murray P, Lin H, Parikh CR. Associations between Deceased-Donor Urine Injury Biomarkers and Kidney Transplant Outcomes. *J Am Soc Nephrol* 2016; **27**: 1534-1543 [PMID: 26374609 DOI: 10.1681/ASN.2015040345]

62 **Nielsen MB**, Krogstrup NV, Nieuwenhuijs-Moeke GJ, Oltean M, Dor FJMF, Jespersen B, Birn H. P-NGAL Day 1 predicts early but not one year graft function following deceased donor kidney transplantation - The CONTEXT study. *PLoS One* 2019; **14**: e0212676 [PMID: 30817778 DOI: 10.1371/journal.pone.0212676]

63 **Koo TY**, Jeong JC, Lee Y, Ko KP, Lee KB, Lee S, Park SJ, Park JB, Han M, Lim HJ, Ahn C, Yang J. Pre-transplant Evaluation of Donor Urinary Biomarkers can Predict Reduced Graft Function After Deceased Donor Kidney Transplantation. *Medicine (Baltimore)* 2016; **95**: e3076 [PMID: 26986138 DOI: 10.1097/MD.0000000000003076]

64 **Li YM**, Li Y, Yan L, Wang H, Wu XJ, Tang JT, Wang LL, Shi YY. Comparison of urine and blood NGAL for early prediction of delayed graft function in adult kidney transplant recipients: a meta-analysis of observational studies. *BMC Nephrol* 2019; **20**: 291 [PMID: 31375084 DOI: 10.1186/s12882-019-1491-y]

65 **Bank JR**, Ruhaak R, Soonawala D, Mayboroda O, Romijn FP, van Kooten C, Cobbaert CM, de Fijter JW. Urinary TIMP-2 Predicts the Presence and Duration of Delayed Graft Function in Donation After Circulatory Death Kidney Transplant Recipients. *Transplantation* 2019; **103**: 1014-1023 [PMID: 30300282 DOI: 10.1097/TP.0000000000002472]

66 **McGuinness D**, Leierer J, Shapter O, Mohammed S, Gingell-Littlejohn M, Kingsmore DB, Little AM, Kerschbaum J, Schneeberger S, Maglione M, Nadalin S, Wagner S, Königsrainer A, Aitken E, Whalen H, Clancy M, McConnachie A, Koppelstaetter C, Stevenson KS, Shiels PG. Identification of Molecular Markers of Delayed Graft Function Based on the Regulation of Biological Ageing. *PLoS One* 2016; **11**: e0146378 [PMID: 26734715 DOI: 10.1371/journal.pone.0146378]

67 **Briggs JD**. Causes of death after renal transplantation. *Nephrol Dial Transplant* 2001; **16**: 1545-1549 [PMID: 11477152 DOI: 10.1093/ndt/16.8.1545]

68 **Foster MC**, Weiner DE, Bostom AG, Carpenter MA, Inker LA, Jarolim P, Joseph AA, Kusek JW, Pesavento T, Pfeffer MA, Rao M, Solomon SD, Levey AS. Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial. *Am J Transplant* 2017; **17**: 2390-2399 [PMID: 28257169 DOI: 10.1111/ajt.14258]

69 **Bansal N**, Carpenter MA, Weiner DE, Levey AS, Pfeffer M, Kusek JW, Cai J, Hunsicker LG, Park M, Bennett M, Liu KD, Hsu CY. Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. *J Am Soc Nephrol* 2016; **27**: 2109-2121 [PMID: 26538631 DOI: 10.1681/ASN.2015030292]

70 **Park M**, Katz R, Shlipak MG, Weiner D, Tracy R, Jotwani V, Hughes-Austin J, Gabbai F, Hsu CY, Pfeffer M, Bansal N, Bostom A, Gutierrez O, Sarnak M, Levey A, Ix JH. Urinary Markers of Fibrosis and Risk of Cardiovascular Events and Death in Kidney Transplant Recipients: The FAVORIT Trial. *Am J Transplant* 2017; **17**: 2640-2649 [PMID: 28371433 DOI: 10.1111/ajt.14284]

71 **Devine PA**, Cardwell C, Maxwell AP. Association of soluble ST2 with all-cause and cardiovascular mortality in renal transplant recipients: a single-centre cohort study. *BMC Nephrol* 2020; **21**: 22 [PMID: 31992225 DOI: 10.1186/s12882-020-1690-6]

72 **Yepes-Calderón M**, Sotomayor CG, Gans ROB, Berger SP, Leuvenink HGD, Tsikas D, Rodrigo R, Navis GJ, Bakker SJL. Post-transplantation plasma malondialdehyde is associated with cardiovascular mortality in renal transplant recipients: a prospective cohort study. *Nephrol Dial Transplant* 2020; **35**: 512-519 [PMID: 32133530 DOI: 10.1093/ndt/gfz288]

73 **Fernández-Ruiz M**, Parra P, López-Medrano F, Ruiz-Merlo T, González E, Polanco N, Origüen J, San Juan R, Andrés A, Aguado JM. Serum sCD30: A promising biomarker for predicting the risk of bacterial infection after kidney transplantation. *Transpl Infect Dis* 2017; **19**: [PMID: 28122147 DOI: 10.1111/tid.12668]

74 **Sadeghi M**, Lahdou I, Opelz G, Mehrabi A, Zeier M, Schnitzler P, Daniel V. IL-23 plasma level is strongly associated with CMV status and reactivation of CMV in renal transplant recipients. *BMC Immunol* 2016; **17**: 35 [PMID: 27716059 DOI: 10.1186/s12865-016-0175-7]

75 **Leone F**, Gigliotti P, La Russa A, Lofaro D, Perri A, Vizza D, Lupinacci S, Toteda G, Bonofiglio M, Presta P, Talarico R, Aquino B, Bonofiglio R. NFKB1 promoter polymorphism: A new predictive marker of cytomegalovirus infection after kidney transplantation. *Transpl Infect Dis* 2019; **21**: e13027 [PMID: 30431214 DOI: 10.1111/tid.13027]

76 **Pinto M**, Dobson S. BK and JC virus: a review. *J Infect* 2014; **68 Suppl 1**: S2-S8 [PMID: 24119828 DOI: 10.1016/j.jinf.2013.09.009]

77 **Kim MH**, Lee YH, Seo JW, Moon H, Kim JS, Kim YG, Jeong KH, Moon JY, Lee TW, Ihm CG, Kim CD, Park JB, Chung BH, Kim YH, Lee SH. Urinary exosomal viral microRNA as a marker of BK virus nephropathy in kidney transplant recipients. *PLoS One* 2017; **12**: e0190068 [PMID: 29267352 DOI: 10.1371/journal.pone.0190068]

78 **Abend JR**, Changala M, Sathe A, Casey F, Kistler A, Chandran S, Howard A, Wojciechowski D. Correlation of BK Virus Neutralizing Serostatus With the Incidence of BK Viremia in Kidney Transplant Recipients. *Transplantation* 2017; **101**: 1495-1505 [PMID: 27854236 DOI: 10.1097/TP.0000000000001261]

79 **Ho J**, Schaub S, Wiebe C, Gao A, Wehmeier C, Koller MT, Hirsch HH, Hopfer H, Nickerson P, Hirt-Minkowski P. Urinary CXCL10 Chemokine Is Associated With Alloimmune and Virus Compartment-Specific Renal Allograft Inflammation. *Transplantation* 2018; **102**: 521-529 [PMID: 28902772 DOI: 10.1097/TP.0000000000001931]

80 **Ahmadpoor P**, Rostaing L. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection. *Transpl Int* 2020; **33**: 824-825 [PMID: 32236983 DOI: 10.1111/tri.13611]

81 **Velazquez-Salinas L**, Verdugo-Rodriguez A, Rodriguez LL, Borca MV. The Role of Interleukin 6 During Viral Infections. *Front Microbiol* 2019; **10**: 1057 [PMID: 31134045 DOI: 10.3389/fmicb.2019.01057]

82 **Lauterio A**, Valsecchi M, Santambrogio S, De Carlis R, Merli M, Calini A, Centonze L, Buscemi V, Bottiroli M, Puoti M, Fumagalli R, De Carlis L. Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab. *Transpl Infect Dis* 2020; : e13334 [PMID: 32449235 DOI: 10.1111/tid.13334]

83 **Hope CM**, Troelnikov A, Hanf W, Jesudason S, Coates PT, Heeger PS, Carroll RP. Peripheral natural killer cell and allo-stimulated T-cell function in kidney transplant recipients associate with cancer risk and immunosuppression-related complications. *Kidney Int* 2015; **88**: 1374-1382 [PMID: 26266834 DOI: 10.1038/ki.2015.237]

84 **Pontrelli P**, Rascio F, Zaza G, Accetturo M, Simone S, Infante B, Furian L, Castellano G, Ditonno P, Battaglia M, Cormio L, Carrieri G, Lupo A, Rigotti P, Gesualdo L, Stallone G, Grandaliano G. Interleukin-27 is a potential marker for the onset of post-transplant malignancies. *Nephrol Dial Transplant* 2019; **34**: 157-166 [PMID: 30059989 DOI: 10.1093/ndt/gfy206]

85 **Garnier AS**, Planchais M, Riou J, Jacquemin C, Ordonez L, Saint-André JP, Croue A, Saoudi A, Delneste Y, Devys A, Boutin I, Subra JF, Duveau A, Augusto JF. Pre-transplant CD45RC expression on blood T cells differentiates patients with cancer and rejection after kidney transplantation. *PLoS One* 2019; **14**: e0214321 [PMID: 30925186 DOI: 10.1371/journal.pone.0214321]

86 **Dhital S.M. (2019) Diabetes in Kidney Transplant Recipients. In: Parajuli S.,** Aziz F. (eds) Kidney Transplant Management. Springer, Cham 113-131 [DOI: 10.1007/978-3-030-00132-2\_10]

87 **Heldal TF**, Ueland T, Jenssen T, Hartmann A, Reisaeter AV, Aukrust P, Michelsen A, Åsberg A. Inflammatory and related biomarkers are associated with post-transplant diabetes mellitus in kidney recipients: a retrospective study. *Transpl Int* 2018; **31**: 510-519 [PMID: 29341300 DOI: 10.1111/tri.13116]

88 **Yepes-Calderón M**, Sotomayor CG, Gomes-Neto AW, Gans ROB, Berger SP, Rimbach G, Esatbeyoglu T, Rodrigo R, Geleijnse JM, Navis GJ, Bakker SJL. Plasma Malondialdehyde and Risk of New-Onset Diabetes after Transplantation in Renal Transplant Recipients: A Prospective Cohort Study. *J Clin Med* 2019; **8**: [PMID: 30987358 DOI: 10.3390/jcm8040453]

89 **O'Connell PJ**, Zhang W, Menon MC, Yi Z, Schröppel B, Gallon L, Luan Y, Rosales IA, Ge Y, Losic B, Xi C, Woytovich C, Keung KL, Wei C, Greene I, Overbey J, Bagiella E, Najafian N, Samaniego M, Djamali A, Alexander SI, Nankivell BJ, Chapman JR, Smith RN, Colvin R, Murphy B. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. *Lancet* 2016; **388**: 983-993 [PMID: 27452608 DOI: 10.1016/S0140-6736(16)30826-1]

90 **Ix JH**, Katz R, Bansal N, Foster M, Weiner DE, Tracy R, Jotwani V, Hughes-Austin J, McKay D, Gabbai F, Hsu CY, Bostom A, Levey AS, Shlipak MG. Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial. *Am J Kidney Dis* 2017; **69**: 410-419 [PMID: 28024930 DOI: 10.1053/j.ajkd.2016.10.019]

91 **Smedbråten J**, Sagedal S, Åsberg A, Hartmann A, Rollag H, Mjøen G, Fagerland MW, Hansen SW, Mollnes TE, Thiel S. Collectin Liver 1 and Collectin Kidney 1 of the Lectin Complement Pathway Are Associated With Mortality After Kidney Transplantation. *Am J Transplant* 2017; **17**: 265-271 [PMID: 27341702 DOI: 10.1111/ajt.13933]

92 **Heylen L**, Thienpont B, Naesens M, Busschaert P, Depreeuw J, Smeets D, Jochmans I, Monbaliu D, Pirenne J, Lerut E, Ghesquiere B, Kuypers D, Lambrechts D, Sprangers B. Ischemia-Induced DNA Hypermethylation during Kidney Transplant Predicts Chronic Allograft Injury. *J Am Soc Nephrol* 2018; **29**: 1566-1576 [PMID: 29610404 DOI: 10.1681/ASN.2017091027]

93 **San Segundo D**, Galván-Espinoza LH, Rodrigo E, Irure J, Ruiz JC, Fernández-Fresnedo G, Riesco L, Bada J, Belmar L, Lopez-Hoyos M. Regulatory T-cell Number in Peripheral Blood at 1 Year Posttransplant as Predictor of Long-term Kidney Graft Survival. *Transplant Direct* 2019; **5**: e426 [PMID: 30882031 DOI: 10.1097/TXD.0000000000000871]

94 **Yang JYC**, Sarwal RD, Sigdel TK, Damm I, Rosenbaum B, Liberto JM, Chan-On C, Arreola-Guerra JM, Alberu J, Vincenti F, Sarwal MM. A urine score for noninvasive accurate diagnosis and prediction of kidney transplant rejection. *Sci Transl Med* 2020; **12**: [PMID: 32188722 DOI: 10.1126/scitranslmed.aba2501]

95 **de Vries LV**, MinoviÄ‡ I, Franssen CFM, van Faassen M, Sanders JS, Berger SP, Navis G, Kema IP, Bakker SJL. The tryptophan/kynurenine pathway, systemic inflammation, and long-term outcome after kidney transplantation. *Am J Physiol Renal Physiol* 2017; **313**: F475-F486 [PMID: 28490533 DOI: 10.1152/ajprenal.00690.2016]

96 **Kostidis S**, Bank JR, Soonawala D, Nevedomskaya E, van Kooten C, Mayboroda OA, de Fijter JW. Urinary metabolites predict prolonged duration of delayed graft function in DCD kidney transplant recipients. *Am J Transplant* 2019; **19**: 110-122 [PMID: 29786954 DOI: 10.1111/ajt.14941]

97 **Irure-Ventura J**, San Segundo D, Rodrigo E, Merino D, Belmar-Vega L, Ruiz San Millán JC, Valero R, Benito A, López-Hoyos M. High Pretransplant BAFF Levels and B-cell Subset Polarized towards a Memory Phenotype as Predictive Biomarkers for Antibody-Mediated Rejection. *Int J Mol Sci* 2020; **21**: [PMID: 31991734 DOI: 10.3390/ijms21030779]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** May 17, 2020

**First decision:** June 3, 2020

**Article in press:** August 25, 2020

**Specialty type:** Transplantation

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Dor FJ, Tafulo S **S-Editor:** Zhang L **L-Editor:** A **P-Editor:** Li JH

**Table 1 Summary of novel biomarker studies of chemokines associated with immunologic outcomes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | *n* | Sample | Biomarkers | Outcome | Study conclusion |
| Rabant *et al*[11], 2015 | 244 | Urine | uCXCL9, uCXCL10 | Rejection | CXCL9/10a correlated with ti+mvi (i+t; g + ptc) CXCL10: Cra diagnosed TCMR and ABMR (AUC> 0.75); CXCL10: Cr + DSAa improved the diagnosis of ABMR (AUC = 0.83) |
| Hricik *et al*[12], 2015 | 21 | Urine | CXCL9 | Rejection | uCXCL9 predicts AR by a median of 15 d before clinical detection |
| Faddoul *et al*[13], 2018 | 184 | Urine and plasma | IFN-γ ELISpot; CXCL9 | ACR | CXCL9 predictive of ACR; IFN-γ predictive of 1 year ↓eGFR; neither predicted 5-yr outcomes |
| Xu *et al*[14], 2018 | 87 | Plasma | circulating fractalkine, IFN-γ and IP-10 | AR | Fractalkine on day 0, IP-10 at +7 and IFN-γ on +7 had the highest *AUC* (0.866) for predicting AR in 1 mo (sensitivity 86.8%; specificity 89.8%) |
| Tefik *et al*[15], 2019 | 65 (9 rejection, 56 stable) | Plasma | IL-2, IL-8 | Rejection | IL-2b and IL-8c predict AR; IL-2b and IL-8d levels correlated with ↓ 3 mo eGFR in the AR group |
| de Holanda *et al*[16], 2018 | 73 | Plasma | sCD30 | Rejection; Graft survival | Plasma CD30 at +7, +14 associated w AR (*P* = 0.036). No difference in 5 yr graft survival |

a*P* < 0.001 *vs* histology. b*P* < 0.05 *vs* non-rejection group. c*P* < 0.02 *vs* non-rejection group. d*P* <0.01 *vs* non-rejection group.u: Urinary; C-X-C: C-terminal amino acid sequence Cystine-X-Cystine; CXCL9: C-X-C motif chemokine ligand nine; CXCL10: C-X-C motif chemokine ligand ten; ti: Total inflammation; mvi: Microvascular inflammation; i: Interstitial inflammation; t: Tubulitis; g: Glomerulitis; ptc: Peritubular capillaritis; Cr: Creatinine; TCMR: T cell-mediated rejection: ABMR: Antibody-mediated rejection; AUC: Area under the curve; DSA: Donor specific antibodies; AR: Acute rejection; ACR: Acute cellular rejection; IFN-γ: Interferon gamma; eGFR: Estimated glomerular filtration rate; IP-10: Interferon gamma-induced protein ten; IL-2: Interleukin-2; IL-8: Interleukin-8; CD30: Cluster of differentiation thirty; sCD30: Soluble cluster of differentiation 30.

**Table 2 Summary of micro-ribonucleic acid-related novel biomarker studies associated with immunologic outcomes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | *n* | Sample | Biomarkers | Outcome | Study conclusion |
| Matz *et al*[17], 2016 | 160 | Plasma | miR-15B, miR-103A, miR-106A | TCMR | miR-15Ba,b, miR-103Aa,b and miR-106Aa,b discriminated patients with stable graft function from patients with TCMR and UTI |
| Matz *et al*[18], 2018 | 111 | Plasma | miR-223-3p; miR-424-3p; miR-145-5p; miR-15b-5p | ABMR, TCMR, IFTA | miR-223-3p, miR-424-3p and miR-145-5p distinguished TCMR and ABMR from stable graft function; mir-145-5P decreased in IFTA (AUC 0.891) compared to stable graft function |
| Millán *et al*[19], 2017 | 80 | Urine | miR-142-3p, miR-210-3p and miR-155-5p, CXCL10 | Rejection | ↑miR-142-3p, ↑miR-155-5p, ↑CXCL10 + ↓miR-210-3p (AUC = 0.875) and CXCL10 (AUC = 0.865) discriminate rejectors and nonrejectors (sensitivity 85%, 84% and specificity 86% and 80% respectively) |
| Halloran *et al*[20], 2017 | 519 | Allograft biopsy | Molecular Microscope® Diagnostic System (MMDx™)/microRNA | TCMR, ABMR | Agreement between MMDx™ and histology = 77% for TCMR, 77% for ABMR, and 76% for no rejection with blinding to histology, HLA. MMDx™c agreed with clinical judgment (87%) more than histology (80%) |
| Ledeganck *et al*[21], 2019 | 11 studies | Allograft biopsy | microRNA | TCMR, ABMR, cABMR | ↑miR-142, miR-155, miR-223 and ↓miR-125, miR-30, miR-204 predict TCMR, ABMR, cABMR |
| Lorenzen *et al*[23], 2015 | 93 | Urine | lcRNA; RP11-354P17.15-001 (L328) | TCMR | RP11-354P17.15-001d (L328) was associated with acute TCMR (*AUC* = 0.76) sensitivity 49%, specificity 95%; L328 can detect subclinical TCMR |

a*P* < 0.001 for TCMR *vs* controls. b*P* < 0.001 for UTI *vs* controls. c*P* < 0.005 *vs* histology. d*P* <0.001 *vs* controls. miR: Mature form of microribonucleic acid; RNA: Ribonucleic acid; TCMR: T cell-mediated rejection; HLA: Human leukocyte antigen; UTI: Urinary tract infection; ABMR: Antibody-mediated rejection; IFTA: Interstitial fibrosis tubular atrophy; AUC: Area under the curve; C-X-C: C-terminal amino acid sequence Cystine-X-Cystine; CXCL10: C-X-C motif chemokine ligand ten; MMDx™: Molecular Microscope® Diagnostic System; cABMR: Chronic antibody-mediated rejection; lcRNA: Long noncoding RNAs.

**Table 3 Summary of leukocyte subclass related biomarkers associated with immunologic outcomes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | *n* | Sample | Biomarkers | Outcome | Study conclusion |
| Luque *et al*[25], 2019 | 175 | Plasma | donor reactive memory B cells (mBC) | ABMR | For-cause bx: mBC in 100% ABMR/DSA+ and most cABMR, +/- DSA [24/30 (80%) and 21/29 (72.4%)]. Protocol bx: mBC > dnDSA was observed at 6 and 24 mo (8.8% *vs* 7.7% and 15.5% *vs* 11.1%) and identified pts with ongoing subABMR (AUC = 0.917, 0.809) |
| Gorbacheva *et al*[26], 2016 |  | Plasma | mCD4 | Rejection | Murine models with sensitized mCD4 T cells had SCr > 1 mg/dL (1.7 ± 0.6 mg/dL by 6–8 d post-transplant) and developed graft failure. At rejection, these recipients had DSA and ↑ frequencies of donor–reactive T cells producing IFN-γ compared with controls |
| Yazdani *et al*[27], 2019 | 95 | Plasma | NK gene expression model -> NK cells | Rejection | NK cells predict ABMRa *vs* no rejection (AUC *=* 0.98); ABMRb *vs* TCMR (AUC = 0.91) as well as histology: 22/24 biopsies with mvi (g + ptc) had ↑ NK levels (AUC *=* 0.89) Moreover, activated NK cells had the best predictive capability of graft failure at 1-2 yr (AUC *=* 0.74). NK cell infiltrationd predicted graft failure independent of histology |
| Cortes-Cerisuelo *et al*[28], 2017 | 23 | Plasma | CD28+CD4+ | Rejection | CD28+CD4+ T cell frequency is associated with rejection on belatacept based IS |

a*P* < 0.001 *vs* controls. b*P* < 0.001 *vs* TCMR. c*P* < 0.0001 *vs* biopsies w/o mvi. d*P* < 0.05 *vs* controls. mBC: Donor reactive memory B-cells; ABMR: Antibody-mediated rejection; DSA: Donor specific antibodies; cABMR: Chronic antibody-mediated rejection; bx: Biopsy; dnDSA: *De novo* donor specific antibodies; pts: Patients; subABMR: Subclinical ABMR; AUC: Area under the curve; mCD4: Memory cluster of differentiation four; SCr: Serum creatinine; IFN-γ: Interferon gamma; mvi: Microvascular inflammation; NK: Natural killer; TCMR: T cell-mediated rejection; CD28+CD4+: Cluster of differentiation twenty eight and cluster of differentiation four; IS: Immunosuppression.

**Table 4 Summary of gene expression related biomarkers associated with immunologic outcomes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | *n* | Sample | Biomarkers | Outcome | Study conclusion |
| Friedewald *et al*[10], 2019 | 308 | Plasma | Blood based biomarker/gene expression profile | Subclinical acute rejection | GEP AR biomarker predicted sc-AR (sensitivity 64%, specificity 87%, PPV *=* 61%, NPV *=* 88%) |
| Zhang *et al*[29], 2019 | 113 | Plasma | TREx | Rejection at 3 mo, Graft failure | TREx predicts sc-AR at 3 mo in 113 KTRs (AUC *=* 0.830; NPV *=* 0.98, PPV *=* 0.79) |
| Crespo *et al*[30], 2017 | 75 | Plasma | kSORT™ + ELISpot | Subclinical rejection | kSORT™ + ELISpot predict sc-ARa, sc-TCMRa and sc-ABMRa (AUC > 0.85) |
| First *et al*[32], 2019 | 192; 45 | Plasma | TruGraf® GEP | Surveillance of patients with stable allograft function | In 87.5% of the cases, investigators’ clinical decisions were influenced by TruGraf® results. In 45 patients TruGraf® supported 87% of clinical decisions with 93% of investigators stating they would use TruGraf® in subsequent patient care |
| Sigdel *et al*[33], 2019 | 150 KTRs (43 stable, 45 AR, 19 borderline AR, 43 BKVN) | Urine | Common rejection module (11 genes) | Rejection | 10/11 genes were elevated in AR when compared to stable graft function. Psmb9 and CXCL10 could classify AR versus stable graft function as accurately as the 11-gene model (sensitivity = 93.6%, specificity = 97.6%); uCRM score differentiate AR from stable graft function (AUC = 0.9886) |

a*P* < 0.001 *vs* controls. GEP: Gene expression profile; AR: Acute rejection; sc-AR: Subclinical acute rejection; PPV: Positive predictive value; NPV: Negative predictive value; TRex: Targeted expression assay; KTRs: Kidney transplant recipients; kSORT™: Kidney Solid Organ Response Test; ELISpot: Enzyme-linked immune absorbent spot; sc-TCMR: Subclinical T cell-mediated rejection; sc-ABMR: Subclinical antibody-mediated rejection; BKVN: BK virus nephropathy; Psmb9: Proteasome 20S Subunit Beta 9; C-X-C: C-terminal amino acid sequence Cystine-X-Cystine; CXCL10: C-X-C motif chemokine ligand ten; uCRM: Urinary common rejection module.

**Table 5 Summary of donor-derived cell-free deoxyribonucleic acid biomarkers associated with immunologic outcomes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | *n* | Sample | Biomarkers | Outcome | Study conclusion |
| Oellerich *et al*[35], 2019 | 189 | Plasma | dd-cfDNA | Rejection | In pts with BPR, dd-cfDNA(cp/mL) was 3.3x and dd-cfDNA(%) 2.0x higher (82 cp/mL; 0.57%) than in stable pts w/o rejection (25 cp/mL; 0.29%). dd-cfDNA abs number > dd-cfDNA % (AUC = 0.73). OR= 7.31 for dd-cfDNA (cp/mL) |
| Stites *et al*[36], 2020 | 79 KTRs with TCMR 1A/borderline rejection | Plasma | dd-cfDNA | eGFR, dnDSA, Future rejection | ↑dd-cfDNA predict adverse outcomes: among patients with ↑dd-cfDNAa, eGFR ↓ by 8.5% vs 0% in ↓dd-cfDNA pts. dnDSA seen in 40% (17/42) *vs* 2.7%b and future or persistent rejection occurred in 9 of 42 ptsa (21.4% *vs* 0%) |
| Bloom *et al*[38],2017 | 102 | Plasma | dd-cfDNA | Rejection | Distinguished any rejection from non-rejection along with ABMR from non-ABMR |
| Huang *et al*[40], 2019 | 63 | Plasma | dd-cfDNA | ABMR | dd-cfDNA discriminated ABMRc [median 1.35%; interquartile range (IQR): 1.10%-1.90%] from no rejection (median 0.38%, IQR: 0.26%-1.10%). dd-cfDNA did not distinguish TCMR from no rejection |
| Whitlam *et al*[41], 2019 | 61 | Plasma | dd-cfDNA | aABMR  cABMR | gd-cfDNA and fraction were predictive of aAMR (AUC *=* 0.92, 0.85) and composite dx of ABMR (AUC *=* 0.91, 0.89). gd-cfDNA w/ modest sensitivity (0.90; 0.85) and specificity (0.88, 0.79) for aAMR and ABMR |

a*P* < 0.005 *vs* low level dd-cfDNA pts. b*P* < 0.0001 *vs* low level dd-cfDNA pts. c*P* < 0.001 *vs* no rejection. dd-cfDNA: Donor derived-cell free deoxyribonucleic acid; Abs: Absolute; BPR: Biopsy proven rejection; AUC: Area under the curve; OR: Odds ratio; KTRs: Kidney transplant recipients; TCMR: T cell-mediated rejection; eGFR: Estimated glomerular filtration rate; dnDSA: *De novo* donor specific antibodies; ABMR: Antibody-mediated rejection; cABMR: Chronic antibody-mediated rejection; IQR: Interquartile range; dx: Diagnosis; aAMR: Acute antibody-mediated rejection; aABMR: Acute antibody mediated rejection; gd-cfDNA: Graft-derived cell-free DNA; Pts: Patients.

**Table 6 Summary of biomarkers associated with graft quality**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | *n* | Sample | Biomarkers | Outcome | Study conclusion |
| Parikh *et al*[46],2016 | 671 | Perfusate | NGAL, L-FABP | 6 mo eGFR | Each doubling of perfusate NGAL and L-FABP were independently associated with ↓6-mo eGFR (1.7mL/min per 1.73m2; 1.48mL/min per 1.73m2 ) |
| Moser *et al*[47], 2017 | 41 | Perfusate | MMP-2, LDH, NGAL | Biomarker levels | MMP-2a,b, LDHa,b, and NGALa,b were found in highest perfusate concentrations in DCD kidneys, followed by DBD and living donor allografts |
| Hamaoui *et al*[48], 2017 | 10 | Perfusate | Perfusate lactate | Perfusion | 10 DCD porcine kidneys perfused *via* HMP with modified AL solutionc had significantly ↓ perfusion lactate levels (3.1 *vs* 4.1 mmol/L) during reperfusion than those in UW solution |
| van Smaalen *et al*[49], 2017 | 390 | Perfusate | Extracellular histone concentration | 1 yr graft survival | (extracellular histone) was associated w/ 1 year graft failure (HR = 1.386) 1 year graft survival was ↑ for the ↓ extracellular histone groupd (83% *vs* 71%) , maintained up to 5 yearse (76% *vs* 65%) |
| Weissenbacher *et al*[50],2019 | 11 | Perfusate | NGAL, KIM-1 | Kidney quality | ↑ perfusate NGAL level was found in the lowest quality kidney. In the perfused kidneys w/o urine recirculation, NGAL and KIM-1 ↓ over time. Small sample size; NGAL/ KIM-1 not predictive of kidney quality |
| Hosgood *et al*[53], 2017 | 56 | Urine | NGAL, endothelin-1 | Kidney quality per EVKP score | ↑ levels of NGAL and ET-1 were associated with ↑ EVKP scoref (*P <* 0.05) |

a*P* < 0.0001 *vs* Donation after brain death kidneys. b*P* < 0.0001 *vs* living donor kidneys. c*P* < 0.05 *vs* Deceased cardiac death donor kidneys perfused with University of Wisconsin solution. d*P* < 0.01 *vs* increased extracellular histone group. e*P* < 0.05 *vs* increased extracellular histone group. f*P* < 0.05 *vs* EVKP group A. NGAL: Neutrophil gelatinase-associated lipocalin; L-FABP: Liver fatty acid binding protein; eGFR: Estimated glomerular filtration rate; MMP-2: Matrix metalloproteinase-2 LDH: Lactate dehydrogenase; DBD: Donation after brain death; DCD: Deceased cardiac death donor; HMP: Hypothermic machine perfusion; AL: Adenosine lidocaine; UW: University of Wisconsin; HR: Hazard ratio; KIM-1: Kidney injury molecule-1; EVKP: *Ex vivo* normothermic kidney perfusion; ET-1: Endothelin-1.

**Table 7 Summary of biomarkers associated with delayed graft function**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | *n* | Sample | Biomarkers | Outcome | Study conclusion |
| Parikh *et al*[46],2016 | 671 | Perfusate | NGAL, IL-18, L-FABP | DGF | Base (NGAL) was significantly ↑ in allografts with DGFa. This was also observed in post values of IL-18a and base/post perfusate L-FABP levelsb.  These biomarkers did not significantly correlate with DGF development on multivariate adjustment |
| van Smaalen *et al*[49], 2017 | 390 | Perfusate | Extracellular histone concentration | DGF | Extracellular histone concentration was significantly ↑ in the DGF group (median 0.70 µg/mL (IQR0.4 to 0.98) compared to grafts that functioned immediatelyc (median, 0.42 (IQR 0.07 to 0.78). Interestingly there was no significant difference in extracellular histone concentration in grafts with primary non-function *vs* DGF |
| van Balkom *et al*[57],2017 | 40 | Perfusate | Leptin, GM-CSF, periostin, plasminogen activator inhibitor-1, osteopontin | DGF | 5 perfusate proteins/158 tested predicted DGF. Leptin and GM-CSF -> most predictive. Validation with 40 kidneys found that leptin, GM-CSF + BMI predict DGF (AUC = 0.89 (95%CI: 0.74 to 1.00), which performed better than KDRI and DGF risk calculator (AUC0.55, 0.59) |
| Roest *et al*[58], 2019 | 48 | Perfusate | microRNA mir-505-3p | DGF | In 8 DCD and DBD donors, ↑ levels of perfusate microRNA mir-505-3p correlated with DGFb (OR1.12). This was confirmed *via* validation of 40 allografts, of which 20 developed DGFb. Interestingly, this predictive capability held true solely for DCD allograftsc |
| Truche *et al*[59], 2019 | 41 | Urine and Plasma | uNGAL, uNAG, LDH, UCr | DGF | DGF -UNGAL, UNAG AUC 1, 0.96 (0.84-1.0) , urinary tubular injury biomarker-to-creatinine ratio, and LDH AUC = 1 and 0.92 (95%CI: 0.73 to 1.0) |
| Pianta *et al*[60], 2015 | 81 | Urine | Urinary clusterin, IL-18, KIM-1, NGAL | DGF | Urinary clusterin predicted DGF at 4 h (AUC = 0.72 (95%CI: 0.57 to 0.97), as did IL-18 , KIM-1 and NGAL; eGFR at 90 d was inversely correlated with urinary clusterin at 12 hb (Pearson *r* = −0.26, and 7 db (Pearson *r* = −0.25) |
| Reese *et al*[61], 2016 | 1304 | Urine | Microalbumin, NGAL, KIM-1, IL-18, L-FABP | AKI, DGF, 6-mo eGFR | Microalbumin, NGAL, KIM-1, IL-18, L-FABP from deceased donors at procurement; predictive of AKI; NGAL associated with DGF (RR= 1.21 (95%CI: 1.02 to 1.43), NGAL and L-FABP associated with lower 6 mo eGFR |
| Nielsen *et al*[62], 2019 | 225 | Plasma and urine | pNGAL, uNGAL uL-FABP, urine cystatin C, urine YLK-40 | DGF, 1 yr mGFR/eGFR | pNGAL 1 d after tx -> associated with DGF. Did not correlate to 12-mo eGFR; no relation w L-FABP, cystatin C, and YLK-40 |
| Koo *et al*[63], 2016 | 94 | Urine | Microalbumin, NGAL, KIM-1, IL-18, L-FABP | DGF, 1 yr graft function | NGAL predicts AKI; NGAL + L-FABP predicts DGF (*AUC* 0.758, 0.704); NGAL + L-FABP + Cr better than DGF calculator and KDPI. L-FABP predictive of 1 yr graft functionb |
| Li *et al*[64], 2019 | 1036 | Urine and plasma | uNGAL, pNGAL | DGF | Composite AUCfor 24 h uNGAL was 0.91 (95%CI*:* 0.89 to 0.94) and the overall DORfor 24 h uNGAL was 24.17; sensitivity 0.88, specificity 0.81. The composite AUCfor 24 h pNGAL was 0.95 (95%CI: 0.93 to 0.97) with an overall DOR for 24 h pNGAL = 43.11 with sensitivity 0.91 and specificity 0.86 |
| Bank *et al*[65], 2019 | 74 (DCD KTRs) | Urine | Urinary TIMP-2 | DGF | TIMP-2/mOsm on day-1 and day-10 identified patients with DGF (AUC = 0.91) and prolonged DGF (*AUC* = 0.80); Consecutive TIMP-2/mOsm values showed a ↓ in TIMP-2/mOsm before an ↑estimated glomerular filtration rate, predicting resolution of fDGF |
| McGuinness *et al*[66], 2016 | 94 |  | hsa-miR-217; hsa-miR-125b | DGF | miRNA + donor age + type donation predicted DGF in 83% of cases (61% sensitivity, 91% specificity) |
| Ledeganck *et al*[21], 2019 | 11 studies | Allograft biopsy | microRNA | DGF | Upregulation of miR-21-3P and miR-182-5p associated with DGF |

a*P* < 0.005 *vs* non-DGF allografts. b*P* < 0.05 *vs* non-DGF allografts. c*P* < 0.001 *vs* immediately functioning grafts. NGAL: Neutrophil gelatinase-associated lipocalin; IL-18: Interleukin eighteen; L-FABP: Liver fatty acid binding protein; DGF: Delayed graft function; IQR: Interquartile range; GM-CSF: Granulocyte-macrophage colony-stimulating factor; BMI: Body mass index; AUC: Area under the curve; KDRI: Kidney donor risk index; RNA: Ribonucleic acid; mir: Pre-microRNA; DCD: Deceased cardiac death donor; DBD: Deceased brain death donor; OR: Odds ratio; u: Urinary; uNGAL: Urinary neutrophil gelatinase-associated lipocalin; uNAG: Urinary N-acetyl-β-glucosaminidase; LDH: Lactate dehydrogenase; UCr: Urine creatinine; KIM-1: Kidney injury molecule-1; CI: Confidence interval; eGFR: Estimated glomerular filtration rate; RR: Relative risk; pNGAL: Plasma neutrophil gelatinase-associated lipocalin; YLK-40: Chitinase-3-like protein mGFR: Measured glomerular filtration rate; KDPI: Kidney donor profile index; DOR: Diagnostic odds ratio; TIMP-2: Tissue inhibitor of metalloproteinases 2; mOsm: Milliosmoles; fDGF: Functional delayed graft function; hsa: Homo sapiens; miR: Mature form of microRNA.

**Table 8 Summary of biomarkers associated with cardiovascular events and cardiovascular mortality**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | *n* | Sample | Biomarkers | Outcome | Study conclusion |
| Foster *et al*[68], 2017 | 508 | Urine and plasma | Cystatin C, B2M, Cr | CV events, Mortality, Kidney failure | HR eGFRcys and HReGFRB2M < 30 *vs* 60+ were 2.02a (95%CI: 1.09 to 3.76) and 2.56b (95%CI: 1.35 to 4.88) for CV events; 3.92c (95%CI 2.11 to 7.31) and 4.09b (95%CI: 2.21 to 7.54) for mortality; and 9.49c (95%CI: 4.28 to 21.00) and 15.53b (95%CI 6.99 to 34.51) for kidney failure |
| Bansal *et al*[69], 2016 | 1027 | Urine | uNGAL, uKIM-1, IL-18, L-FABP, UCr | CV events, Graft failure, mortality | Each ↑ log in uNGAL/Cr associated with a 24% ↑ risk of CV events (aHR *=* 1.24 (95%CI: 1.06 to 1.45), graft failure (1.40; 1.16 to 1.68), and risk of death (1.44; 1.26 to 1.65). uKIM-1/Cr and IL-18/Cr associated with higher risk of death (1.29; 1.03 to 1.61 and 1.25; 1.04 to 1.49 per log increase) |
| Park *et al*[70], 2017 | 1184 (300 CVD, 371 death, 513 random sub-cohort) | Urine | urine alpha 1 microglobulin [A1M], monocyte chemoattractant protein‐1 [MCP‐1], procollagen type I [PINP] and type III [PIIINP] N‐terminal amino peptide) | CV events, Death | ↑uA1M (HR per doubling of biomarker = 1.40 (95%CI: 1.21 to 1.62), MCP‐1 [HR 1.18 (1.03 to 1.36)], and PINP [HR= 1.13 (1.03 to 1.23)]were associated with CVD events and death (HR per doubling α1m = 1.51 (95%CI: 1.32 to 1.72); MCP‐1 = 1.31 (1.13 to 1.51); PINP = 1.11 (1.03 to 1.20) |
| Devine *et al*[71], 2020 | 367 | Plasma | ST2 | CV events, CV mortality, All-cause mortality | ↑ ST2 was associated with CV events(aHR = 1.31 (95% CI: 1.00 to 1.73); significantly for CV mortalityd (aHR = 1.61; (95%CI: 1.07 to 2.41; *P* = 0.022), The addition of ST2, to risk prediction models for CV mortality/events failed to improve their predictive accuracy |
| Yepes- Calderón *et al*[72], 2020 | 604 | Plasma | Malondialdehyde | CV mortality | During a follow-up period, 110 KTRs died, with 40% CV death. MDA was significantly associated with the risk for CV mortality. The association between MDA concentration and the risk for CV mortality was stronger in KTRs with ↓ eGFR [HR 2.09 (95%CI: 1.45-3.00) per 1-SD increment] |

a*P <* 0.05 *vs* eGFRcys > 60. b*P <* 0.005 *vs* eGFRB2M > 60. c*P* < 0.005 *vs* eGFRcys > 60. d*P* < 0.05 *vs* low ST2 group. B2M: Beta-2-microglobulin; Cr: Creatinine; CV: Cardiovascular; HR: Hazard ratio; eGFR: Estimated glomerular filtration rate; eGFRcys:Estimated glomerular filtration rate based on cysteine; eGFRB2M: Estimated glomerular filtration rate based on beta-2-microglobulin; uNGAL: Urinary neutrophil gelatinase-associated lipocalin; KIM-1: Kidney injury molecule 1; IL-18: Interleukin eighteen; L-FABP: Liver fatty acid binding protein; UCr: Urine creatinine; aHR: Adjusted hazard ratio; A1M: Alpha 1 microglobulin; MCP-1: Monocyte chemoattractant protein-1; PINP: Procollagen type I intact N-terminal peptide; PIIINP: Procollagen type III intact N-terminal peptide; ST2: Cardiac biomarker; MDA: Malondialdehyde; SD: Standard deviation.

**Table 9 Summary of biomarkers associated with infectious outcomes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | *n* | Sample | Biomarkers | Outcome | Study conclusion |
| Fernández-Ruiz *et al*[73], 2017 | 100 | Plasma | sCD30 | Bacterial infection | sCD30 correlates to bacterial infection at baselinea and 1 moa, 3 moa, and 6 moa after KT. Patients with sCD30 ≥ 13.5 ng/mL had lower 12-mo bacterial infection-free survivalb (35.0% *vs* 80.0%) Baseline sCD30 levels ≥ 13.5 ng/mL is a risk factor for infectionc (HR: 4.65; 2.05-10.53) |
| Sadeghi *et al*[74], 2016 | 70 | Plasma | IL-23 | CMV infection | Patients with post-KT CMV disease (*n* = 13; 150 ± 106 d post-KT range 41–363 d) had higher pre-KT IL-23d (8.6 ± 4.4 *vs* 8.0 ± 17) and IL-23/Cr ratiosd than patients w/o CMV disease post-KT (*n* = 57). Pre-KT IL-23 plasma level of > 7 pg/mL is a risk factor for post-KT CMV infection/reactivation and symptomatic infectione (RR = 4.50, 95%CI: 1.23 to 16.52) *ROC* curve analysis post-KT CMV disease showed a sensitivity of 69% and a specificity of 67% |
| Leone *et al*[75], 2019 | 189 | Plasma | 94ins/delE37delATTG NFKB1 polymorphism | CMV infection | 65% of CMV infections occurred in ins/ins group. Survival free from CMV was 54.7% for ins/ins group and 79.4% for del carriers one-year post-KT. A multivariate regression for del carriers showed a ↓ risk of CMV infectionf and recurrence for ins/ins KTRsg (*HR*= 0.224, 0.307) |
| Kim *et al*[77], 2017 | 385 | Urine | Urine microRNA bkv-miR-B1-5p and bkv-miR-B1-3p | BKVN | ↑ bkv-miR-B1-5p and bkv-miR-B1-3p in KTRs w biopsy proven BKVN distinguished them from disease free recipients (AUC = 0.989, 0.985). Only 13 KTRs with BKVN |
| Abend *et al*[78],2017 | 116 | Plasma | Donor BK virus antibody, recipient BK virus antibody | Post-transplant BK viremia | Donor BK virus antibody seropositivity correlated to post-transplant BK viremiah (OR= 5.0; 95%CI:1.9-12.7). The authors did not examine for BKVN however |
| Ho *et al*[79], 2018 | 107 | Urine | CXCL10 | BKVN | ↑CXCL10 correlated with t+ii (uCXCL10/creatinine, 1.23 ng/mmol *vs* 0.46 ng/mmol; *AUC* = 0.69) and mvi, specifically ptci (uCXCL10/creatinine, 1.72 ng/mmol *vs* 0.46 ng/mmol; AUC = 0.69) compared to normal histology. Urinary CXCL10i corresponded with BKV, but not CMV viremia. These urine CXCL10 findings were confirmed in the independent validation set |

a*P* < 0.05 *vs* kidney transplant recipients without bacterial infection. b*P <* 0.0001 *vs* kidney transplant recipients with sCD30 < 13.5 ng/mL. c*P* < 0.001 *vs* kidney transplant recipients with sCD30 < 13.5 ng/mL. d*P* < 0.05 *vs* kidney transplant recipients w/o CMV disease. e*P <* 0.05 *vs* kidney transplant recipients with pre-Tx IL 23 < 7 pg/mL. f*P* < 0.005 *vs* ins/ins carriers. g*P <* 0.05 *vs* del carriers. h*P* < 0.0001 *vs* seronegative BK virus antibody donors. i*P < 0.05 vs* low CXCL10 KTRs.

sCD30: Soluble cluster of differentiation 30; KT: Kidney transplant; HR: Hazard ratio; IL-23: Interleukin twenty three; CMV: Cytomegalovirus; RR: Relative risk; Cr: Creatinine; ROC: Receiver operating characteristic; ins: Insertion; del: Deletion; NFKB1: Nuclear Factor kappa-light-chain-enhancer of activated B cells; KTRs: Kidney transplant recipients; bkv: BK viral; RNA: Ribonucleic acid; miR: Mature form of micro RNA; BKVN: BK virus nephropathy; AUC: Area under the curve; OR: Odds ratio; CI: Confidence interval; C-X-C: C-terminal amino acid sequence Cystine-X-Cystine; CXCL10: C-X-C motif chemokine ligand ten; t: Tubulitis; i: Interstitial inflammation; mvi: Microvascular inflammation; ptc: Peritubular capillaritis.

**Table 10 Summary of biomarkers associated with post-transplant malignancy**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | *n* | Sample | Biomarkers | Outcome | Study conclusion |
| Hope *et al*[83], 2015 | 82 (56 KTRs +malignancy, 26 KTRs - malignancy) | Plasma | LDH; IFN-γ; ELISpot | Post- transplant malignancy | Low NK cell function -> HR 2.1 (0.97-5.00) metastatic Ca, Ca-related death, septic death |
| Pontrelli *et al*[84], 2019 | 156: 93 KTRs, 34 controls + malignancy, 29 healthy subjects | Plasma | IL-27 | Post-transplant malignancy | IL-27 plasma levels were able to discriminate patients with post-transplant neoplasia with a specificity of 80% and a sensitivity of 81% |
| Garnier *et al*[85], 2019 | 89 | Plasma | CD4+CD45RC | Post-transplant malignancy | KTRs with a low CD4+CD45RChigh population (< 51.9%) carried a 3.7 fold risk of cancera (HR *=* 3.71 (95%CI: 1.24 to 11.1), CD4+CD45high population having a 20-fold higher risk of rejectionb (HR *=* 21.7 (95%CI: 2.67-176.2) |

a*P <* 0.05 *vs* kidney transplant recipients with a high CD4+CD45R population. b*P* < 0.001 *vs* Kidney transplant recipients with a low CD4+CD45R population. KTR: Kidney transplant recipient; LDH: Lactate dehydrogenase; IFN-γ: Interferon gamma; ELISpot: Enzyme-linked immunosorbent spot assay; NK: Natural killer; HR: Hazard ratio; Ca: Cancer; IL-27: Interleukin twenty seven; CD4+CD45RC: CD45RC – cluster of differentiation four + forty five isoform with alternative mRNA splicing of exon 6; CI: Confidence interval.

**Table 11 Summary of biomarkers associated with post-transplant diabetes mellitus**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | *n* | Sample | Biomarkers | Outcome | Study conclusion |
| Heldal *et al*[87], 2018 | 852 | Plasma | 20 biomarkers | PTDM | 6/20 biomarkers associated with PTDM; significant include soluble TNF type 1a Pentraxin 3a macrophage migration inhibitory factora and endothelial protein C receptorb |
| Yepes-Calderón *et al*[88], 2019 | 516 | Plasma | Malondialdehyde | PTDM | MDA was inversely associated with PTDM, independent of immunosuppressive therapy, transplant-specific covariates, lifestyle, inflammation, and metabolism parametersa (HR, 0.55; 95%CI, 0.36-0.83 per 1-SD increase) |

a*P* < 0.05 *vs* kidney transplant recipients without Post transplant diabetes mellitus. b*P* < 0.005 *vs* kidney transplant recipients without Post transplant diabetes mellitus. PTDM: Post transplant diabetes mellitus; TNF: Tumor necrosis factor; MDA: Malondialdehyde; HR: Hazard ratio; SD: Standard deviation; CI: Confidence interval.

**Table 12 Summary of biomarkers associated with graft survival and/or patient survival**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | *n* | Sample | Biomarkers | Dysfunction | Study conclusion |
| de Holanda *et al*[16], 2018 | 73 | Plasma | sCD30 | Rejection; Graft survival | sCD30 at +7, +14 associated with ARa. No difference in 5 yr graft survival |
| Koo *et al*[63], 2016 | 94 | Urine | microalbumin, NGAL, KIM-1, IL-18, L-FABP | DGF, slow graft function , 1 yr graft function | NGAL predicts AKI; NGAL + L-FABP predicts DGF, slow graft function (AUC 0.758, 0.704); NGAL + L-FABP + Cr better than DGF calculator and KDPI. L-FABP predictive of 1 yr graft functionb |
| Foster *et al*[68], 2017 | 508 | Urine and plasma | Cystatin C, B2M, Cr | CV events, Mortality, Kidney failure | HReGFRcys and HR eGFRB2M < 30 *vs* 60+ were 2.02c (1.09-3.76) and 2.56d (1.35-4.88) for CV events; 3.92e (2.11-7.31) and 4.09d (2.21-7.54) for mortality; and 9.49e (4.28-21.00) and 15.53d (6.99-34.51) for kidney failure |
| Bansal *et al*[69], 2016 | 1027 | Urine | uNGAL, KIM-1, IL-18, L-FABP, Ucr | CV events, Graft failure, mortality | Each ↑ log in uNGAL/Cr associated with a 24% ↑ risk of CV events (aHR 1.24; 1.06 to 1.45), graft failure (1.40; 1.16 to 1.68), and risk of death (1.44; 1.26 to 1.65). uKIM-1/Cr and IL-18/Cr associated with higher risk of death (1.29; 1.03 to 1.61 and 1.25;1.04 to 1.49 per log increase) |
| O’Connell *et al*[89], 2016 | 204 | Biopsy | Gene set of 13 genes | IFTA, Graft loss at 2/3 yr | Gene set prediction > clinicopathologic variables (AUC 0.967 > AUC 0.706, AUC 0.806) for IFTA; predicted graft loss at 2 and 3 years (AUC 0.842, 0.844), validated in 2 public datasets |
| Ix *et al*[90], 2017 | 748 | Urine | Urine A1M, MCP-1, procollagen type III and type I amino-terminal amino pro-peptide | Graft failure | In adjusted models, ↑ concentrations of urine A1M (HR per doubling, 1.73; 1.43-2.08) and MCP-1 (HR per doubling, 1.60; 1.32-1.93) were associated with allograft failure. With the adjustment, urine A1M (HRper doubling, 1.76; 95%CI: 1.27-2.44]) and MCP-1 levels (HR per doubling, 1.49; 95%CI: 1.17-1.89) remained associated with allograft failure |
| Heylen *et al*[92], 2018 | 154 | Biopsy | DNA methylation | 1-yr graft function | ↑ methylation risk scoref at transplant predicted chronic injury at 1 yr (OR 45; 98 to 499; *P* < 0.001; AUC 0.919) *vs* standard baseline clinical risk factors, including age, donor criteria, donor last SCr, CIT, anastomosis time, HLA mismatches (combined AUC 0.743) sensitivity, specificity, and PPV, NPV values of MRS-based ROC curves were 90%, 90%, 95%, and 82% |
| Park *et al*[70], 2017 | 1184 (300 CVD, 371 death, 513 random sub-cohort) | Urine | Urine A1M MCP‐1, PINP and PIIINP | CV events, Mortality | In adjusted models, higher urine AlM (HRper doubling of biomarker = 1.40 (95%CI: 1.21 to 1.62), MCP‐1 [HR = 1.18 (1.03 to 1.36)], and PINP [HR = 1.13 (95%CI: 1.03 to 1.23) were associated with CVD events. These three markers were also associated with death (HR per doubling A1M = 1.51 (95%CI: 1.32 to 1.72); MCP‐1 = 1.31 (1.13 to 1.51); PINP = 1.11 (95%CI:1.03 to 1.20) |
| Smedbråten *et al*[91], 2017 | 382 | Plasma | CL-L1, CL-K1 | CV mortality, Graft survival, Patient survival | ↑CL-L1 (≥ 376 ng/mL) and ↑CL-K1 (≥ 304 ng/mL) levels at transplantation were associated with mortality in multivariate Cox analysesg [HR = 1.50 (95%CI: 1.09 to 2.07) and HR *=* 1.43 (95%CI:1.02 to 1.99)] ↑CL-K1 levels were associated with CV mortality. No association between measured biomarkers and death-censored graft loss was found |
| San Segundo *et al*[93], 2019 | 133 | Plasma | Abs number peripheral blood Treg cells | Death-censored graft survival | ↑ Treg cells 1 yr post-KTh showed better DCGL (5-yr survival, 92.5% *vs* 81.4%). 1-yr Treg cellsh showed a *ROC* *AUC* of 63.1% (95%CI: 52.9 to 73.2) for predicting DCGL. After multivariate Cox regression analysis, an ↑ number of peripheral blood Treg cellsh was protective factor for DCGL (HR = 0.961 (95%CI: 0.924 to 0.998), irrespective of 1-yr proteinuria and renal function |

a*P* < 0.05 *vs* grafts without rejection. b*P <* 0.05 vs immediate function grafts. c*P <* 0.05 *vs* eGFRcys > 60. d*P <* 0.005 *vs* eGFRB2M > 60. e*P* < 0.005 *vs* eGFRcys >60. f*P <* 0.005 *vs* low methylation risk score at transplant. g*P* < 0.05 *vs* KTRs with collectin levels below cutoff. h*P* < 0.05 *vs* KTRs with absolute number of peripheral blood Treg cells below threshold. sCD30: Soluble cluster of differentiation thirty; AR: Acute rejection; uNGAL: Urinary neutrophil gelatinase-associated lipocalin; KIM-1: Kidney injury molecule 1; IL-18: Interleukin eighteen; L-FABP: Liver fatty acid binding protein; DGF: Delayed graft function; AKI: Acute kidney injury; AUC: Area under the curve; KDPI: Kidney donor profile index; B2M: Beta-2-microglobulin; Cr: Creatinine; CV: Cardiovascular; HR: Hazard ratio; Abs: Absolute; eGFR: Estimated glomerular filtration rate; eGFRcys: Estimated glomerular filtration rate based on cysteine; eGFRB2M : Estimated glomerular filtration rate based on beta-2-microglobulin; u: Urine; UCr: Urine creatinine; aHR: Adjusted hazard ratio; IFTA: Interstitial fibrosis tubular atrophy; A1M: Alpha 1 microglobulin; MCP-1: Monocyte chemoattractant protein-1; PINP: Procollagen type I intact N-terminal peptide; PIIINP: Procollagen type III intact N-terminal peptide; DNA: Deoxyribonucleic acid; OR: Odds ratio; SCr: Serum creatinine; CIT: Cold ischemia time; HLA: Human leukocyte antigen; PPV: Positive predictive value; NPV: Negative predictive value; MRS: Methylation risk score; CI: Confidence interval; CL-L1: Collectin liver-1: CL-K1-collectin kidney-1; Treg: Regulatory T cells; KT: Kidney transplant; DCGL: 95% eath censored graft loss; ROC: Receiver operating characteristic.